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Abstract 
Setting 
Study conducted in Tygerberg, Cape Town in South Africa. 
Hypothesis 
Host biomarkers associated with the antimycobacterial immune response during active 
infection with M. tuberculosis and during anti-tuberculosis chemotherapy are indicative of 
bacterial killing in the host and can be used in models to predict eventual treatment outcome. 
Objectives 
1. To investigate immune parameters that were selected in a biological context as 
biomarkers of the extent of disease and early response to anti-tuberculosis treatment. 
2. To use selected immune parameters to characterise fast and slow responders to anti-
tuberculosis therapy. 
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Findings 
Evaluation of cytokine multiplex fluorescent bead-based immunoassays as a screening tool 
in the search for biomarkers 
The data showed that cytokine multiplex fluorescent bead-based immunoassays 
achieved acceptable recoveries to detect antigen-specific IFN- responses in whole blood 
supernatant making it attractive for biomarker screening. However, proper optimisation needs 
to be done and proper controls included when using these kits. 
Markers of extent of disease 
High levels of CRP at diagnosis were found to be associated with the presence of 
multiple cavities on chest X-rays. A high level of suPAR and sICAM-1 at diagnosis were 
associated with the extent of alveolar disease. Also significant were the associations between 
the level of granzyme B, LAG-3 at diagnosis and the size of the cavities. No significant 
associations were observed between sTNFRs or DR5 with the chest X-ray grading of 
tuberculosis disease.  
Early classification of fast and slow responders to anti-tuberculosis treatment 
After cross-validation classification, discriminant analysis (DA) and support vector 
machine (SVM) analysis of selected immune parameters (sICAM-1 CRP, granzyme B, 
suPAR, sTNFRs, LAG-3 and CD3dim/CD56+ (% of CD45+) resulted in a 75% to 100% 
correct classification of the fast responders and a 82% to 100% correct classification of the 
slow responders when using DA. For SVM, the correct classification of the fast responders 
ranged from 88% to 100%, and that for the slow responders ranged from 95% to 100%.  
Differential gene expression in fast and slow responders to treatment 
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Direct comparison of fast and slow responders showed that IL-4 transcripts were 
significantly higher in the fast responders at week one after initiation of treatment when 
compared to slow responders. IL-42 was also differentially expressed. Although IL- was 
significantly up-regulated in both fast and slow responders after one week of treatment 
compared to diagnosis, IL- expression was more than two folds higher in slow responders 
than in fast responders. No significant differences between the fast and slow responders were 
observed in the expression of TGF-, TGF-RII, Foxp3 and GATA-3. 
Conclusion 
Predictive models for differential anti-tuberculous treatment responses combining host 
proteins are promising and should be included in larger prospective studies to find the optimal 
markers for inclusion into clinical trials of new drugs and for implementation into clinical 
practice. 
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Opsomming 
Ligging 
Studie onderneem in Tygerberg, Kaapstad, Suid-Afrika. 
Hipotese 
Gasheerbiomerkers wat verband hou met die antimikobakteriële immuunrespons 
tydens aktiewe infeksie deur M. tuberculosis en tydens teentuberkulose chemoterapie dui op 
bakteriële doding in die gasheer en kan in modelle gebruik word om die uiteindelike uitkoms 
van die behandeling te voorspel. 
Doelwitte 
1. Om gekose immuunparameters in ’n biologiese konteks as biomerkers van die omvang 
van siekte en vroeë reaksie op behandeling te ondersoek. 
2. Om gekose immuunparameters te gebruik om vinnige en stadige reageerders op 
teentuberkulosebehandeling te karakteriseer.  
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Bevindings 
Evaluering van die sitokien veelvuldige fluoresseer-pêrelbaseerde immuuntoets (cytokine 
multiplex fluorescent bead-based immunoassays) as ’n siftingsinstrument in die soeke na 
biomerkers 
Die data het getoon dat die sitokien veelvuldige fluoresseer-pêrelgebaseerde 
immuuntoets in staat was om antigeenspesifieke IFN--respons te meet wat dit aanloklik maak 
vir biomerkersifting. Sorgvuldige optimering moet egter gedoen word en behoorlike beheer 
moet ingesluit word wanneer hierdie stelle gebruik word. 
Merkers van omvang van siekte 
Hoë vlakke van CRP by diagnose is getoon om verband te hou met die 
teenwoordigheid van veelvoudige holtes op die pasiënte se borskas x-strale. Hoë vlakke van 
suPAR en sICAM-1 by diagnose was assosieer met die omvang van alveolêre siekte.  Die 
assosiasie tussen die vlakke van granzyme B, LAG-3 by diagnose en die grootte van die holtes 
was ook betekenisvol. Daar was geen betekenisvolle assosiasies toe sTNFRs of DR5 en die 
borskas x-straalgradering van tuberkulosesiekte nie.  
Vroeë klassifikasie van vinnige en stadige reageerders op teentuberkulosebehandeling 
Ná klassifikasie op grond van kruisstawing het diskriminant-analise (DA) en 
ondersteuningsvektormasjiene (SVM) van geselekteerde immuunparameters (sICAM-1 CRP, 
gransiem B, suPAR, sTNFRs, LAG-3 en CD3dim/CD56+ (% van CD45+)) gelei tot ’n 75% 
tot 100% korrekte klassifikasie van die vinnige reageerders met DA en ’n 82% tot 100% 
korrekte klassifikasie van stadige reageerders. Vir SVM het die korrekte klassifikasie van 
vinnige reageerders gewissel van 88% tot 100%, en vir stadige reageerders het dit gewissel 
van 95% tot 100%.  
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Differensiële geenuitdrukking in vinnige en stadige reageerders op behandeling  
In vergelyking met die vlak by diagnose is die uitdrukkingsvlak van IL-4 in die 
vinnige reageerders betekenisvol opgereguleer met ’n faktor van 9.2 teen die eerste week ná 
die aanvang van behandeling, in kontras met die stadige reageerders. Daar was geen verskille 
tussen die vinnige en die stadige reageerders met betrekking tot die uitdrukking van TGF-, 
TGF-RII, Foxp3 en GATA-3 nie. 
Gevolgtrekking 
Voorspellende modelle vir differensiële tuberkulose behandelingsresponse wat 
gasheerproteïene kombineer, hou belofte in en behoort in groter prospektiewe studies ingesluit 
te word om die mees geskikte merkers te vind vir insluiting in kliniese proewe van nuwe 
middels en vir implementasie in kliniese praktyk. 
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_______________________________________________________ 
CHAPTER 1: Tuberculosis: Burden, Infection, Immunology and Treatment 
_______________________________________________________ 
Declaration:  
The information contained in this chapter was used in: 
1. A review article: Correlates for disease progression and prognosis during concurrent 
HIV/TB infection  
Joel Fleury Djoba Siawaya,* Morten Ruhwald, Jesper Eugen-Olsen, Gerhard Walzl. 
International Journal of Infectious Diseases (2007) 11, 2890-2899. 
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1.1 Burden of tuberculosis 
Mycobacterium tuberculosis bacilli (M. tuberculosis), an obligate, aerobe-transmitted 
bacterium, is known for its ability to enter a dormant state under adverse metabolic conditions 
and delay its multiplication for years, which has helped its survival in humans (1). 
Worldwide, the growing epidemic of TB is alarming. An estimated one third of the world 
population is infected with M. tuberculosis and at risk of developing the disease. The lifetime 
risk of progressing to active TB when latently infected with TB is about 5% (1). This escalates 
to over 10% per annum when co-infected with HIV (2). In addition, the risk of mortality due 
to HIV/TB co-infection is twice that of HIV infection alone (3). With more than eight million 
people progressing to active tuberculosis every year, and a death rate of about 25%, 
pulmonary tuberculosis is one of the most life-threatening human diseases. More than 90% of 
global TB cases and deaths occur in the developing world (4). In sub-Saharan Africa, over 1.5 
million tuberculosis cases are declared per year (5). Based on the 2007 World Health 
Organization report, South Africa has one of the worst TB rates in the world, with a TB 
incidence of 600 cases per 100 000 persons and 270 178 new cases each year (6). 
Despite the availability of anti-tuberculosis chemotherapy, which have been available 
for over half a century, the tuberculosis infection rate is not yet under control and increases 
each year (7;8). Several factors are involved in the rise of tuberculosis: the ability of the 
bacteria to subvert the host immune pathway, inadequate TB management programmes, poor 
treatment adherence by patients and the emergence of drug-resistant M. tuberculosis strains. It 
has been predicted that if TB control is not improved, one billion people will be newly 
infected with TB by 2020, over 150 million people will become diseased and 36 million will 
die (9). 
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1.2 Infection, immunology and pathology of tuberculosis 
1.2.1 Infection and primary response 
Tuberculosis (TB) is a contagious disease. The germs are propelled into the air when 
infectious individuals sneeze, cough or spit. Although the inhalation of a small number of 
these germs by a person is sufficient to be infected, the likelihood of M. tuberculosis 
transmission is increased by the number of bacilli inhaled, the frequency of exposure, and 
presumably the general nutritional and immune status or immune profile of the exposed 
subject (10;11). 
M. tuberculosis enters the body through the respiratory tract and reaches the lungs, the 
initial site of infection. The primary defence against M. tuberculosis in the lower respiratory 
tract involves alveolar macrophages (12). Macrophages engulf M. tuberculosis, through 
complement, mannose or scavenger receptors in a vacuole called the phagosome (13). After 
bacilli uptake, the macrophages induce phagosome-lysosome fusion and acidification through 
IFN- (14) and Ca2+-dependent signalling mechanisms (15). The subsequent reduction in the 
intra-phagosomal pH and the production of nitrogen and oxygen radicals (16;17) lead to 
growth inhibition and killing of bacilli. Parallel to this, infected macrophages induce cell-
mediated and adaptive immunity (12;13;18-21). The development of cell-mediated immunity 
(CMI) occurs within 14 to 42 days of infection (12). CMI is characterised by granuloma 
formation by activated macrophages and lymphocytes (12;13;20). T-cell stimulation through 
cytokine- (such as IFN-and TNF-mediated mechanisms increases the anti-mycobacterial 
activity of macrophages and enhances their ability to control the infection (22). 
Neutrophils, natural killer cells (NK) and dendritic cells have been shown to be 
actively involved in immunity to tuberculosis. Studies have shown that neutrophils provide 
defensins for macrophage-mediated killing and can even bring about killing of M. tuberculosis 
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(12;23). NK cells can directly kill the pathogens or may lyse M. tuberculosis-infected cells by 
inducing apoptosis (programmed cell death) (12;24). It has been shown that macrophage 
apoptosis results in reduced viability of the mycobacterium (25). 
1.2.2 Cell-mediated immune response 
The protective immune response to M. tuberculosis relies on CMI (26;27). The 
development of CMI occurs within 14 to 42 days of infection (12). CMI is characterised by 
the mobilisation of activated macrophages and lymphocytes into lesions, leading to granuloma 
formation (12;20). Infected macrophages and dendritic cells (DCs) process and present 
mycobacterial peptides to T-cells. T-cells, through cytokine- (IFN-and TNF-mediated 
mechanisms, increase the anti-mycobacterial activity of the macrophages and enhances their 
ability to control the infection (26;27). Dendritic cells are seen as crucial in the production of 
an effective adaptive immune response due to their ability to carry antigens to lymphoid 
tissue, where the interaction with CD4 T-cells occurs (28). A few weeks post-infection, the 
number of activated CD4+ and CD8+ T-cells in the lung-draining lymph nodes increases and 
these cells display an effector/memory phenotype (CD44hiCD45loCD62L-); approximately 
half of these cells are CD69+, designated to interact with antigen-presenting cells (APCs) 
through the major histocompatibility complex (MHC) I and II. CD4+ T-cells are major 
effector cells in CMI against M. tuberculosis, and their principal function is to support the 
intracellular killing of M. tuberculosis in infected macrophages by secreting cytokines such as 
IFN-γ and TNF-α, which are crucial for macrophage activation (12;18;19). CD8+ T-cells are 
actively involved in killing M. tuberculosis-infected macrophages (29). However, CD8+ T-
cells may also contribute to IFN-γ-dependent macrophage activation, leading to intracellular 
killing of M. tuberculosis by macrophages (30). 
In most people, CMI controls, but fails to completely clear, the infection. The bacilli 
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can remain alive within the granuloma, in a state of latency that can persist for years without 
causing the disease. Nevertheless, progression to disease can happen any time upon 
reactivation due to the weakening of the immune system (1;19;31). 
1.2.3 Immunopathology: The door to immune evasion 
A successful host response to an invading pathogen requires precise coordination of 
the immune players (32). The recognition of a pathogen by phagocytes induces cell activation 
and cytokine and chemokine secretion, which lead to the establishment a cytokine-chemokine 
network (32). Through a complex process of regulation and cross-regulation, this network 
influences the interplay of immune effectors. Cytokines are double edged sword any 
disequilibrium of their intricate balance may lead to adverse outcome. The magnitude and 
type of cytokines produced, may boost host protective mechanisms but can also lead to tissue 
injury, fever and cachexia (33;34). 
M. tuberculosis possesses numerous immune evasion strategies. Initially, M. 
tuberculosis persistence depends on its ability to resist the antimicrobial activities of alveolar 
macrophages. One of the crucial evasion strategies used by the bacilli is the induction of a 
powerful inflammatory response, leading to immunopathology, or alternatively the 
establishment of a compromising anti-inflammatory response, driven by the need of the host 
to prevent immune-mediated damage. Either mechanism may be exploited by M. tuberculosis 
to promote its survival and its transmission to neighbouring non-activated macrophages 
(35;36). Other M. tuberculosis evasion strategies include prevention of macrophage apoptosis 
and interference with the response to IFN-and with phagosome development (18), 
modulation of antigen presentation (19;37) and modulation of the secretion of oxygen radical 
scavengers (38). In addition, infected antigen-presenting cells (APCs) contribute to defective 
T-cell proliferation and function through the production of immunosuppressive cytokines 
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(TGF-, IL-10) (19;39) and the activation of CD4+ CD25+ regulatory T-cells, which have 
been reported to display immunosuppressive properties (40-42). 
1. 3 Directly observed short course anti-tuberculosis therapy, follow up, 
evaluation and identification of patients at risk for treatment failure and 
relapse 
The directly observed short course therapy (DOTS) is a six-month regimen divided 
into two phases, the intensive phase and the continuation phase. The intensive phase consists 
of two months of five-times-a-week isoniazid (INH), ethambutol (EMB), rifampin (RIF) and 
pyrazinamide (PZA). The continuation phase consists of four months of five-times-a-week 
INH and RIF. However, the transfer of patients from the intensive phase to the continuation 
phase depends on the conversion of their sputum direct smears to negative (Essential Drugs 
Programme South Africa 2003 Edition). The International Union Against Tuberculosis and 
Lung Disease (IUATLD) advises that patients who failed to convert to sputum smear or 
culture negative by the end of the intensive phase of treatment (slow responders) remain on 
the intensive phase of treatment for another month whereas, patients with negative sputum 
smear or culture after two month of intensive therapy (fast responders) are started on the 
continuation phase regimen.  
Treatment failure occurs in 1 to 6% of drug susceptible patient that completed DOTS 
(43;44). These patients are more susceptible to developing drug resistance and may then 
become vectors of drug resistant strain transmission (45;46). Relapse into active tuberculosis 
after initial cure occurs in 2 to 7% of patients with drug-susceptible isolates treated with 
contemporary 6 month anti-tuberculosis therapy (47). The risk of relapse may be increased by 
adverse reactions to therapy (47-49) and by the presence of residual cavitations on chest 
radiography (49-51) at the end of treatment. 
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The intensive phase of treatment is crucial in prevention of treatment failure, relapse 
and emergence of drug resistance. The presences of cavities on chest x-ray radiograph at 
diagnosis and a positive sputum smear or culture at the end of the intensive phase of treatment 
were shown to characterize patients at high risk for treatment failure or relapse (52;53). 
Different mechanisms may be responsible for the delay of sputum smear or culture conversion 
in patients during DOT. Bacterial burden and extensive cavitary disease at diagnosis (46;52), 
drug malabsorption (54;55) and metabolism (56) during treatment have been the reported 
causes of the differential response observed in patients during anti-tuberculosis treatment. 
Therefore it will be particularly important to identify patients at risk for poor response or 
predict the intensive phase outcome as early as possible after initiation of treatment. This will 
allow the appropriate measures such as drug regimen adjustment to be taken early to minimize 
treatment failure, relapse and the emergence of drug resistance. 
Continuous monitoring of bacterial activity by sputum culture during the course of 
anti-TB chemotherapy is very useful in the assessment of treatment efficacy. A parameter has 
emerged with important potential in the assessment of patient progress during treatment: time 
to detection (TTD), also known as time to positivity (TTP). TTP represents the time to 
detectable growth of M. tuberculosis in culture. Hanna et al. (57) were amongst the first to 
observe that TTP of M. tuberculosis increased in samples of patients receiving anti-TB 
therapy and that no change in TTP correlated with poor response during treatment. Further 
evidence of the potential use of TTP as an early indicator of treatment effectiveness comes 
from the study by Epstein et al. (58) that showed that TTP of M. tuberculosis in sputum 
culture correlates with response to anti-TB therapy. 
However, the use of M. tuberculosis culture-based tests for the assessment of TB 
treatment response have important limitations as a substantial proportion of HIV positive TB 
cases have a negative sputum smear at diagnosis (59;60). Moreover, these tests can take 
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several weeks to achieve results (61) and they are of no benefit in HIV patients where extra-
pulmonary TB frequently occurs. Cultures-based tests are also expensive and are often not 
available in resource constraint settings. Thus the identification of affordable and simple tests 
for host correlates of TB treatment efficacy would be of great importance for clinical 
management and for clinical trials of urgently needed new antituberculous drugs. 
1.4 Looking into the future of anti-tuberculosis therapy - from diagnosing 
the disease to predicting treatment outcomes 
Definitions  
 Biomarker: It is a objectively measured and evaluated characteristic that is 
used as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Wikipedia). 
 Surrogate marker: A biomarker intended to substitute for a clinical endpoint. 
The measurement of surrogate markers provides a way to test the effectiveness 
of a treatment (Wikipedia). 
The International Union Against Tuberculosis and Lung Disease (IUATLD) currently 
recommends the week eight of anti-tuberculosis (TB) treatment sputum status as a surrogate 
marker for the evaluation of response to therapy for patients undergoing directly observed 
short course anti-TB chemotherapy (DOTS) (62). Implementation of the IUATLD 
recommendations has certainly improved TB care, although there are limitations to the current 
evaluation process, mainly because two months is too long a wait to establish a favourable or 
poor response to anti-TB treatment and make a clinical decision. During this two-month 
period, the mycobacterium may have time to develop resistance to anti-TB drugs (63). In 
addition, the overall duration of therapy has serious implications for patient adherence to 
therapy and places a serious strain on healthcare systems servicing developing countries, as 
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they struggle to afford full implementation of the recommended treatment programme (six 
months of directly observed therapy). The process of drug development and validation is also 
affected by the current evaluation process, especially when monitoring clinical drug trials of 
new drugs, and the two-month delay wastes resources and time. Current literature suggests 
that it may be possible not only to identify patients who require longer than six-month TB 
treatment regimens in order to prevent recurrence, but, more importantly, to identify the 
majority of patients who would only require a shorter antibiotic treatment course (47;64). If 
we were able to stratify TB patients at the time of diagnosis or shortly after the start of 
treatment into risk groups for recurrence and into groups requiring different durations of 
treatment, TB programmes might be able to concentrate their efforts on ensuring strict 
adherence to short (three to four month) treatment regimens in the vast majority of patients 
and to reserve longer treatment options for those with a higher risk of recurrence. To improve 
the effectiveness of therapeutic interventions for TB, it may be necessary to take a more 
individualised treatment approach or at least an approach based on stratification of patients 
according to a risk scale for adverse treatment response (delayed response, failed treatment or 
recurrence after cure). Such an approach requires appropriate biomarkers that are measurable 
early during treatment. For all these reasons the search for surrogate markers that can provide 
primary measurements of treatment effectiveness and clinical prognosis would be important. 
Facilitating the development and validation of new therapeutic strategies (the right treatment 
for the right patients at the right time), minimising drug tolerance and resistance due to sub-
optimal treatment, and accelerating or shortening clinical trials of new anti-TB drugs could 
result from the use of such markers. The interest in finding such biomarkers is growing, 
judged by the emphasis placed on biomarker research by the World Health Organization 
(WHO), the European and Developing Countries Clinical Trials Partnership (EDCTP), and the 
Bill and Melinda Gates Foundation (BMGF).  
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In the context of drug development, early bactericidal activity (EBA), which 
quantitatively assesses changes in colony forming units (CFU) in sputum during a few days of 
therapy, has emerged as a potential surrogate marker for drug sterilising activity. However, as 
highlighted by Burman (65), EBA has not proved efficient in predicting or identifying 
bacterial sterilisation, an essential component of anti-tuberculous drug regimens offered by 
key drugs like rifampicin and PZA. Nevertheless EBA may still be useful for the evaluation of 
the spectrum of activity of new drugs (66;67) and for the comparison of anti-TB regimens 
(68). Other measures such as sputum M. tuberculosis messenger RNA (69;70), sputum and 
serum cytokine levels (71) were shown to be promising as markers for response to anti-
tuberculosis treatment and mycobacterial clearance. However, some concerns have been 
raised regarding the use of host markers such as cytokines as biomarkers for the assessment of 
therapy. The use of prognostic or diagnostic biomarkers traditionally requires such markers to 
be specifically associated with the targeted disease. The immune response, however, has many 
redundant mechanisms for specific diseases and such mechanisms are also involved in 
responses to multiple types of pathogens. This makes host biomarkers sensitivity and 
specificity challenging. It therefore is generally accepted that the model validating the end 
point should be designed on a set of markers rather than a single marker. In TB, for example, 
Brahmbhatt et al. (72) and Veenstra et al. (73) recently showed that this concept holds 
promise. Furthermore, with advances in technology and knowledge of physiological and 
pathogenic features of TB we can now embark on the targeted investigation of markers in 
biological context to assess their prognostic power for anti-TB therapy efficacy and outcome. 
More prospective studies need to be done to validate the long list of potential biomarkers. 
There is a need to screen candidate surrogate markers in smaller groups of patients before 
engaging in a large-scale validation, as suggested by Gosling et al. (74) for clinical trials. 
These prospective studies should be comprehensively designed and include clinically well-
defined patients (e.g. extent of disease, time of culture conversion and time to positivity (TTP) 
Stellenbosch University  http://scholar.sun.ac.za
 29 
with different treatment outcomes (e.g. culture positive or negative after two month of 
therapy, cured, treatment failed and relapse) in order to adequately screen biomarkers 
associated with different end points. 
Candidate sets of biomarkers associated with clinical end points of interest should be 
validated in large-scale studies before being implemented for clinical use. In clinical settings, 
validated biomarkers should be applied with care, as other possible aetiologies, such as 
different infections, need to be ruled out or taken into consideration. Although the TB-
biomarker field is challenging, pursuing this research area must be prioritised so that the 
healthcare system can better assess patient therapy, so that tools for cost-effective evaluation 
of new drugs can be found and for improved control of the TB pandemic. 
1.5 Present study: Biomarkers for TB treatment response: objectives, and 
rational. 
1.5.1 Objectives 
The ultimate outcome for which predictive markers are needed is relapse after initial 
cure. However, well-characterized patients with relapse and with available biological samples 
for biomarker testing are rare. Therefore, the primary aims of this work were: 
 To investigate targeted bio-molecules as surrogate markers for the extent of disease at 
treatment onset. 
 To investigate targeted bio-molecules as predictive markers of early response to anti-
tuberculosis therapy as defined by week eight Ziehl-Neelsen sputum smear microscopy or 
Bactec culture status.  
Both the extent of radiological disease prior to treatment and the early response during 
treatment are known determinants of treatment failure and relapse. It was anticipated that 
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markers may be found that will be suitable for validation in future large multi-sites studies 
prior to the development of tests for implementation in clinical management and in clinical 
trial settings. 
1.5.2 Hypothesis 
The magnitude of changes in host parameters associated with the antimycobacterial 
immune response during active M. tuberculosis infection and during the course of anti-
tuberculosis therapy is indicative of host-pathogen interactions and could be used to predict 
eventual treatment outcome. 
 
1.6 Candidate biomarkers 
Soluble urokinase plasminogen activator receptor (suPAR) 
Urokinase plasminogen activator receptor (uPAR) is a cell-surface molecule to which 
urokinase plasminogen activator (uPA) binds prior to activation. uPA and its receptor (uPAR) 
are involved in different physiological processes, including tissue remodelling and cell 
adhesion, migration and invasion (75;76). The prognostic power of suPAR has already been 
demonstrated in some diseases. Regarding human immunodeficiency virus, there is evidence 
that suPAR is a strong prognosis indicator of disease progression and patient survival (77). In 
cancer patients, suPAR has shown itself to be valuable in the assessment of prognosis and 
tumour recurrence (78). In tuberculosis, Eugen-Olsen et al. demonstrated that suPAR 
concentrations were elevated in TB patients and associated with mortality (79). They 
suggested the potential use of suPAR as a marker of treatment efficacy, a claim that needs to 
be investigated further.  
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Intracellular adhesion molecule type 1(ICAM-1) 
ICAM is involved in immune cell recruitment and the maintenance of granuloma 
structure in the host response to TB. López Ramírez et al (80) showed that M. tuberculosis 
infected monocytes had increased and sutained expression of ICAM-1. They suggested that 
M. tuberculosis induced ICAM-1 up-regulation promotes the induction and maintenance of 
cell mediated immune response needed to clear the infection. Soluble ICAM-1 has also been 
reported to be a sensitive marker of tuberculosis activity and anti-tuberculosis drug action in 
humans (80;81). Many studies have demonstrated that the sICAM-1 levels of TB patients 
were significantly lower after treatment compared to the levels before treatment, making it a 
candidate marker for the therapy efficacy (80-82). 
C-reactive protein (CRP) 
During tuberculosis, host clearance of the pathogen may be dependent on its capacity 
to efficiently activate macrophages to bind and ingest M. tuberculosis, a process in which 
CRP is actively involved. CRP is known to interact with cell-surface receptors, resulting in 
pathogen opsonisation and enhanced phagocytosis (83-85). In tuberculosis infection, CRP has 
been reported to increase significantly in patients with active tuberculosis and is linked to 
extensive disease (86-89). Furthermore, CRP was shown to be very sensitive to treatment, 
with its level normalising within days of therapy (86;89). This makes CRP a good candidate 
marker for early evaluation of treatment response. 
Lymphocyte activation gene 3 (LAG-3/CD223) 
LAG-3 is selectively expressed in activated T- and NK-cells and has been reported to 
negatively regulate their function (90;91). The LAG-3 gene was showed to act as an immune 
system regulator that keeps the immune response under control through regulatory T-cell 
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action and prevents an excessive and detrimental response (92). In the absence of LAG-3, the 
ability of regulatory T-cells to control the action of effectors T-cells was inhibited (92). 
Lienhardt et al. showed that patients with favourable treatment outcomes had higher levels of 
sLAG-3 two to three months after the initiation of anti-tuberculosis treatment and at the end of 
treatment (93). Also, Triebel et al. reported that sLAG-3 may be a prognostic marker in some 
forms of breast cancer (94). In the light of these observations, sLAG-3 certainly qualifies as a 
potential candidate biomarker for treatment response. 
Granzyme B 
Apoptosis of infected cells is believed to play a role in controlling TB infection (24). 
However, M. tuberculosis-induced T-cell apoptosis has been shown to reduce M. tuberculosis-
stimulated IFN-and IL-2 production (12). Furthermore, granzyme B was identified by 
Gondek et al. as one of the key factors in immunosuppression mediated by CD 4+ CD 25+ T-
regulatory cells (24;40). One way or another, the evaluation of the apoptosis rate is important, 
as it carries useful information on a magnitude of host-pathogen interactions. Because 
granzyme B is a cofactor in the apoptosis process (95), its level may be used to assess 
apoptosis and it would be interesting to explore its potential as a surrogate marker for early 
treatment evaluation. 
Tumour necrosis factor (TNF)- and its receptors 
TNF- is a pro-inflammatory cytokine secreted by macrophages, dendritic cells and T-
cells. This cytokine is required to contain M. tuberculosis by walling off infection through the 
induction of granuloma formation (12;13;96). A further contribution of TNF- in the control 
of M. tuberculosis resides in its ability to induce apoptosis of infected cells by binding to their 
cell-surface receptors (TNFRI and II) (97). However, in excess TNF- leads to severe tissue 
destruction (13;98). The release of sTNFRs is seen as a regulatory mechanism aimed to keep 
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TNF-activity under control and limit TNF-associated immunopathology (97;99). 
Conversely, however, the release of TNFRs, which results in the inactivation of TNF- may 
lead to immune evasion by M. tuberculosis (99) 
Experiments conducted on M. tuberculosis-infected macrophages revealed that 
antimycobacterial therapy significantly reduces the percentage of cells producing TNF- 
(100). In addition, investigating the characteristics and clinical value of serum changes of pro-
inflammatory cytokines and their receptors in patients with pulmonary tuberculosis and during 
anti-tuberculosis treatment, Tang et al. found that the serum levels of TNF-, and soluble 
tumour necrosis factor receptors (sTNFRs), were significantly higher in both active and 
inactive tuberculosis groups. After two months’ anti-tuberculosis treatment, the serum levels 
of TNF- and sTNFRs were significantly lower than before therapy in 15 cases out of 17 
(101). Juffermans et al. (34) also reported the modulation of TNF- and showed that, during 
TB treatment, levels of sTNFRI, and sTNFRII were higher in patients with active TB than in 
healthy contacts and that sTNFRs declined in the patients during treatment. These findings set 
up TNF- and sTNFRs as interesting candidates markers of treatment response.  
Death receptor (DR)-5 
DR5 is a member of the TNF-related apoptosis-inducing ligand (TRAIL) receptor 
family. Contrary to TNF- induced apoptosis, TRAIL-DR5-induced apoptosis is much less 
toxic (102). To date, no study has yet investigated DR5 in the context of TB. Thus, 
investigating DR5 secretion during active TB and anti-tuberculosis treatment will give 
additional insight into the host immune response to TB. 
Interleukin-4 (IL-4) 
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IL-4 is secreted mostly by Th2-cells and its role in human tuberculosis is not fully 
understood, although excess production of IL-4 during tuberculosis is associated with a 
depressed Th1 response and might be detrimental to the host (13;103). Studies have reported 
an association between the level of IL-4 expression and disease severity (103),(104). 
Controversially it has also been suggested that IL-4 might play a role in protective immunity 
against TB, as Sugawara et al. (105) demonstrated that M. tuberculosis infected IL-4 knockout 
mice had high M. tuberculosis colony-forming unit (CFU). Also, there
 
is evidence that 
increased IL-4 secretion enhances TNF- toxicity (103) and promotes TNF--mediated 
apoptosis
 
in M. tuberculosis-activated lymphocytes (106). 
The discovery of IL-4δ2, an IL-4 splice variant and IL-4 antagonist, brought new 
insight of immune regulation and problems with its assessment. Commonly used 
immunoassays for IL-4 do not differentiate between IL-4 and its splice variant and it is now 
clear that IL-4 levels have to be interpreted together with IL-4δ2 expression levels. Studies 
have revealed increased expression of IL-4δ2 in healthy contacts (107) or individuals with 
latent TB contrarily to patients with active TB who showed low expression of IL-4δ2 and 
increased IL-4 expression (108). Also it has been reported that TB patients had greater levels 
of mRNA for both cytokines when compared to healthy controls and that only IL-4δ2 level 
increased in parallel
 
with IFN- after anti-tuberculous treatment (109), which make both IL-4 
and IL-4δ2 candidate markers for the evaluation of patients response to therapy. 
Transforming growth factor beta (TGF-) and its receptors type two 
TGF- is highly pleiotropic and is known to affect a number of cells of the immune 
system (110). It has been shown that the combined production of IL-10 and TGF- may act to 
down-modulate host protective immunity to M. tuberculosis (20;42;111;112). TGF- was 
reported to be present in the granulomatous lesions of TB patients and secreted by human 
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monocytes after stimulation with M. tuberculosis (12;20). This cytokine has important anti-
inflammatory effects, including deactivation of macrophage production of oxygen and nitric 
radicals, T-cell inhibition and proliferation and down regulation of IFN- (20;42;112-114). 
TGF- RI and RII co-expression is required for cellular responses to TGF- and may act to 
down-modulate host immunity. It has also been shown that inflammation signals like LPS or 
IFN- induce a down-modulation of TGF-R expression that is accompanied by a diminished 
ability
 
of the cells to respond to TGF- (111;112).  
GATA-3 transcription factor  
The occurrence of a Th2-type response in TB infection has always been considered as 
one of the factors diminishing the effectiveness of Th1 cells against M. tuberculosis. Thus we 
feel it is important to include Th2-type response markers in the list of candidate surrogate 
markers. Because analysis of cytokine protein levels in TB patients usually makes it difficult 
to demonstrate the presence of a Th2 response, the expression level of mRNA for GATA-3, 
which is a Th2 cell-specific transcription factor, should be the best way to establish the 
occurrence of a Th2-type response in TB patients and its prognosis value. In the literature, the 
GATA-3 transcription factor was reported to control Th2-specific cytokine expression and to 
function as a negative regulator of the development of Th1 cells independently of is ability to 
up regulate Th2-type cytokines (115;116). Interestingly, Hirsch CS et al showed the degree of 
suppression decreased with the time on treatment (114). 
Forkhead box P3 (FOXP3) 
FOXP3 is implicated in the development and function of CD4 + CD25+ regulatory T-
cells and can be used as a marker of its activity. CD4+ CD25+ regulatory T-cells have been 
reported to be implicated in immunosuppression (40). It would be interesting to investigate 
FOXP3 expression in TB patients and assess its informative value in the anti-tuberculosis 
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treatment response. 
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_______________________________________________________ 
CHAPTER 2: Materials and Methods 
_______________________________________________________ 
2.1 Study design 
2.1.1 Setting 
The study was conducted in the Cape Town metropolitan area in South Africa, where 
the prevalence of new smears or cultures positive for TB was 313/100 000 population per year 
between 1993 and 1998 (117). 
2.1.1.1 Study population 
For this study, 12 healthy community controls and 29 HIV-negative newly diagnosed 
sputum smear and Bactec culture-positive patients, infected with drug susceptible M. 
tuberculosis, were selected. Nine were excluded for either non-compliance with treatment, 
multidrug-resistant TB, refusal of HIV test or incomplete follow-up visits. Postero-anterior 
and lateral chest X-rays were taken of all the patients at the beginning of chemotherapy and 
graded for extent of disease. In addition, the time to positivity (TTP) for each patient at each 
time point was known. 
2.1.1.2 Eligibility and exclusion criteria  
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a) Eligibility criteria 
 Two samples Ziehl-Neelsen sputum -positive smear microscopy for M. tuberculosis 
 Two samples one Ziehl-Neelsen sputum -positive smear microscopy and one Bactec 
culture positive for M. tuberculosis 
 One sputum sample that was both smear positive and culture positive for M. 
tuberculosis 
 One Ziehl-Neelsen sputum -positive smear microscopy, in conjunction with a chest 
radiograph typical of pulmonary tuberculosis 
b) Exclusion criteria 
 Previous TB disease  
 Any other mycobacterial disease 
 HIV infection  
 Refusal of HIV testing 
 Drug-resistant tuberculosis at diagnosis 
 Incomplete follow-up or not documented visits  
2.1.1.3 Chest X-ray grading  
Standard postero-anterior and lateral chest radiographs were taken prior to therapy and 
were read by a pulmonologist who was unaware of patient clinical history and using a 
standard method (118). The radiological extent of disease was graded according to the total 
lung area opacity in relation to the size of the right upper lobe or the size of one entire lung. 
The grading included the following categories: i) alveolar disease less that the right upper lobe 
area, ii) equal to the right upper lobe, iii) more than the right upper lobe and iv) more than one 
whole lung. Disease was considered to be moderate if the total area of radiological 
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involvement was less than or equal to the right upper lobe and severe if more than the right 
upper lobe was affected. The presence, number and size of cavities were also graded 
independently from the total alveolar involvement.  
2.1.1.4 Treatment protocol 
The patients received the six-month directly observed short course anti-tuberculosis 
therapy recommended by the South African National Tuberculosis Programme (based on 
WHO TB guidelines) and were subjected to strict adherence control throughout the treatment. 
The drug regimen consisted of a weight-related fixed combination of isoniazid (320 mg/day to 
400 mg/day), rifampin (480 mg/day to 600 mg/day), ethambutol (800 mg/day to 1 200 
mg/day) and pyrazinamide (1 000 mg/day to 1 250 mg/day) during the two months that 
constituted the intensive phase, followed by rifampicin and isoniazid during the four months 
of the continuation phase. 
2.1.1.5 Monitoring of bacteriology and classification of patients into treatment response and 
outcome groups 
Mycobacterial culture was done using the automated BACTEC 12B liquid radiometric 
method (Becton-Dickinson, MD, Bethesda, USA). BACTEC 12B vials were incubated at 37 
C and the growth index read daily at an identical time to limit reading variability. The TTP 
was recorded as the number of days required for each vial to reach a growth index of ≥10. 
Cultures were monitored for 60 days before being classified as negative. Mycobacterial drug 
susceptibility testing for resistance to first- and second line drugs was done using the 
BACTEC method (ref: BACTEC 460TB Systems product and procedure manual, Becton-
Dickinson Diagnostic Instrument Systems, Sparks, Md., 1996) at diagnosis and at the end of 
therapy. Direct sputum smear microscopy was performed using the Ziehl-Neelsen method.  
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Sputum smear ZN stains and BACTEC cultures were done on the first and the third 
day of treatment and at week one, two, four, eight, thirteen and 26 after the initiation of 
chemotherapy. Patients were classified into fast or slow responders to chemotherapy based on 
their BACTEC culture status at week eight (culture positive/culture negative) after being 
started on treatment. 
2.1.2 Selection of patients 
The study finally included 12 healthy community controls and 20 HIV-negative active 
TB patients (11 males and nine females from 18 to 51 years old) with positive sputum smear 
and culture at diagnosis. After the intensive phase of chemotherapy (two months), Bactec 
sputum culture identified eight fast responders and 12 slow responders. 
2.2 Evaluation of cytokine multiplex fluorescent bead-based immunoassays 
as screening tool for the search of biomarkers 
The evaluation of three commercially available cytokines multiplex assays was carried 
out to establish their suitability for biomarkers screening and limits. 
2.2.1 Definitions  
Recovery: Ratio of the observed amount of cytokine compared to the expected known amount 
of cytokine in a sample, expressed as a percentage. An acceptable recovery falls within the 
range of 70 – 130 % (Bio-Rad Principles of Curve Fitting for Multiplex Sandwich 
Immunoassays, Rev B). 
The following formula was used to calculate recovery:  
(Observed Concentration in spiked sample – Observed Concentration in unspiked sample) X 100 
Expected concentration (amount of recombinant cytokine used to spike sample) 
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Linearity: Ratio of the observed amount of cytokine in diluted sample compared to the total 
amount of cytokine in undiluted sample, multiplied by the coefficient of dilution and 
expressed in percentage. 
The following formula was used to calculate linearity: 
(Observed Concentration in diluted Sample) X (Coefficient of dilution) X 100 
Total Concentration of cytokine in undiluted sample 
Recovery and linearity definitions and calculations were obtained from the RnD-Systems 
spike and recovery immunoassay sample validation protocol. 
Reading: Reported fluorescence of the sample 
Positive reading: Reported fluorescence of a sample that is above background fluorescence 
and corresponds to a positive concentration. 
RP1: RP1 represents the fluorescence channel used for assay quantification. Low RP1 is the 
fluorescent channel recommended for quantification of a wide range of cytokines with a wide 
dynamic range of concentrations; whereas high RP1 is recommended for quantification of low 
concentrations of cytokines as it provides greater sensitivity. 
5 PL-(parameters logistic) Regression Curve: A standard curve build upon a five 
parameters logistic equation and that corrects for asymmetry in the curve shape. 
2.2.2 Methodology 
This study followed an integrated methodology, comparing 3 commercially available 
multi-plex Luminex kits (Bio-Rad’s Cytokine 17-plex kit; Linco Inc’s 29-plex kit; and RnD 
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System’s Fluorokine-Multi Analytes Profiling (MAP) kit as well as the RnD Systems IFN- 
Quantikine ELISA kit. We used the following two approaches: 1) Measurement of 
recombinant cytokines in serum and in unstimulated whole blood supernatant samples, each 
spiked with serial dilutions of the multiplex standard provided with the Luminex kits in order 
to calculate the recovery (accuracy) of the assay for each of the different cytokines; 2) 
Measurement of native induced IFN- in vitro in whole blood supernatant and peripheral 
blood mononuclear cell (PBMC) culture supernatants where whole blood supernatant and 
PBMCs were stimulated with Mycobacterium tuberculosis (M. tuberculosis) antigens or 
Bacille Calmette Guerin (BCG). The following three studies were done: 
Study 1: Comparison of the recovery of IFN-γ levels in serum and whole blood supernatant 
between Bio-Rad cytokine assays versus the RnD Systems Quantikine IFN-γ ELISA 
Study 2: Bio-Rad 17-plex cytokine assay recovery study in whole blood supernatant 
Study 3: Bio-Rad 17-plex, Linco 29-plex and RnD Systems fluorokine-(MAP) assay 
comparison study. 
Studies 1 and 2 and the first part of study 3 made use of spiked (therefore known 
concentrations of recombinant cytokines) samples, with known concentrations of recombinant 
cytokines, to compare recovery and accuracy between the different kits. The second part of 
study 3 assesses not only the recovery of different kits but also the ability of the different 
Luminex kits to measure the concentration of IFN-γ in unmanipulated (unspiked) samples 
where IFN-γ levels were measured by ELISA as a gold standard test. 
2.2.3 Study 1: Comparison of the Bio-plex (Bio-Rad) cytokine assay versus the RnD 
Systems Quantikine IFN- ELISA  
Sample preparation 
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The following samples were included:  
1. Unspiked and spiked serum from a healthy laboratory donor diluted one in four with 
sample diluent as recommended by the manufacturer.  
2. Unspiked and spiked unstimulated supernatant from a six-day whole blood culture 
assay diluted one in 10 in RPMI-1640 (GIBCO). 
3. Unspiked and spiked unstimulated culture supernatant from a seven-day PBMC 
culture assay where PBMCs were resuspended at 1 x 10
6
 cells/ml in RPMI-1640 
(GIBCO) and 10 % AB serum (Sigma Aldrich).  
4. Unspiked culture supernatant from whole blood and PBMC assays, as described 
above, stimulated with live BCG (SSI 241103 Statens Serum Institute, Denmark) for 
seven days. 
Controls included:  
1. Standard diluent + RPMI-1640 (1:1) spiked with recombinant IFN- from the RnD 
Quantikine kit standard (control 1) and  
2. Sample diluent + RPMI-1640 (1:1) spiked with recombinant IFN- from the RnD 
Quantikine kit standard (control 2)  
Spiking of samples and controls was performed at a concentration of 500 pg/ml with 
recombinant cytokine from the RnD IFN- Quantikine kit. 
Bio-Rad human 17-plex assay (Study 1) 
A Bio-Rad human cytokine 17-plex kit (cat# 171A11171) was carried out as per the 
manufacturer’s instructions. Briefly, a standard vial from the Bio-Rad human cytokine 17-plex 
kit containing 500 000 pg of lyophilised recombinant multiplex standard (standard control # 
CO2722) was reconstituted in 0.5 ml of Bio-Rad standard diluent (cat # 171304000) to 250 
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000 pg/ml. The reconstituted standard was further diluted one in ten to 25 000 pg/ml, and then 
serially diluted one in four to produce a nine-point standard curve ranging from 0.5 pg/ml to 
25 000 pg/ml, either in matrix (i) kit standard diluent alone for the measurement of cytokines 
in serum (Standard curve 1), or in matrix (ii) kit standard diluent mixed 1:1 with RPMI-1640 
(Sigma Aldrich cat # R0883) for the measurement of cytokines in culture supernatants 
(standard curve 2). The 25 000 pg/ml standard in matrix (i) (standard diluent alone) was also 
used to spike the samples and controls, as described below. The standard curve was run in 
duplicate, while samples and controls were run in singlet. A 50 μl volume of each sample, 
control or standard was added to a 96 well plate (provided with the kit) containing 50 μl of 
antibody coated fluorescent beads. Biotinylated secondary and streptavidin-PE antibodies 
were added to the plate with alternate incubation and washing steps. After the last wash step, 
125 μl of wash buffer was added to the wells, the plate was incubated and subsequently read 
on the Bio-plex array reader, using a 5 PL regression curve to plot the standard curve. 
Samples and controls were read at both a low RP1 target setting (used to maximize assay 
sensitivity when the expected concentrations are below 3 200 pg/ml) and a high RP1 target 
setting (used for broad range concentrations) on the Bio-plex suspension array using a high 
throughput fluidics (HTF) system (cat# 171000005). Data was subsequently analysed using 
the Bio-plex manager software, version 3.  
RnD Systems Quantikine IFN- ELISA (study 1) 
The ELISA was done using the RnD Systems IFN-γ Quantikine ELISA kit (cat# 
DIF50) as per the manufacturer’s instructions. Briefly, lyophilised Quantikine standard was 
reconstituted in distilled water and serially diluted one in two in kit standard diluent to 
produce a seven-point standard curve ranging from 15.6 pg/ml to 1000 pg/ml. Thereafter, 100 
µl of assay diluent was added to designated wells in a 96-well polystyrene microplate 
(provided with the kit) coated with polyclonal antibody against IFN-γ, followed immediately 
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by 100 µl of standard, sample or control. The standard curve, samples and controls were run 
in duplicate. The plate was incubated for two hours at room temperature, washed and 
thereafter 200 µl of horseradish peroxydase (HRP)-conjugated IFN-γ antibody followed by 
200 µl of substrate solution was added to the wells, followed by another incubation period and 
washing step between the two additions. After 30 minutes of incubation, 50 µl of stop solution 
was added to the wells and the plate read at 450 nm, with the wavelength correction set at 570 
nm, on a multi-detection microplate reader (Bio-Tek instruments Inc, part # 7081000). Sample 
concentrations were determined using the KC4 microplate data analysis software, version 
3.34, revision 12.  
2.2.4 Study 2: Bio-Rad human 17-plex assay recovery study 
Bio-Rad human 17-plex assay (Study 2) 
The Bio-Rad human cytokine 17-plex assay was carried out as per the manufacturer’s 
instructions, with a few exceptions as stipulated below. The standard vial was reconstituted in 
unstimulated whole blood assay supernatant (one in ten whole blood with RPMI-1640 
(GIBCO), incubated at 37˚C, 5% CO2 for six days) and not in the standard diluent, as 
recommended by the manufacturer, This was done in order to ensure that the matrix used in 
the generation of the standard curve resembled that of the samples as closely as possible. 
Briefly, a nine-point standard curve was generated by performing serial dilutions of the 
reconstituted standard (lot # 5004060). In order to assess recovery, supernatant samples SN1, 
SN2 and SN3 were spiked at three different concentrations with recombinant cytokine using 
the Bio-plex kit standard. Samples were run in duplicate. In order to keep the matrix of the 
spiked samples as similar as possible to the matrix of the standard curve, the volume of 
reconstituted standard used to spike the samples in all experiments was kept to a minimum of 
10 µl to minimize pippeting error. 
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2.2.5 Study 3: Bio-plex, Linco-plex and RnD Systems fluorokine-(MAP) assay 
comparison study  
Bio-Rad human 17-plex assay (Study 3) 
The standard curve was generated and the assay conducted as described above in the 
section on the Bio-Rad human 17-plex assay study 2. Two sets of samples were used. The first 
set was generated using whole blood from 5 healthy laboratory donor diluted one in ten with 
RPMI-1640 with glutamax and stimulated with different Mycobacterium tuberculosis derived 
antigens, (generously donated by Tom Ottenhoff, Leiden University. See table 3.3 in the result 
section for the antigens names), and a phytohaemagglutinin (PHA)-stimulated positive 
control. Unstimulated culture supernatant served as a negative control. The second set of 
samples was generated from unstimulated whole blood culture as described above. 
Supernatants were harvested on day seven and spiked at five different concentrations with 
recombinant cytokine from the Bio-Rad standard (lot # 5004060, table 2.1), the results of 
which were used to calculate recovery. The assay was conducted and plate read as described 
before.  
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Table 2.1: Expected concentrations of cytokines in the spiked supernatant samples 
(pg/ml) using the Bio-Rad assay. Whole blood supernatant samples were assessed for 
endogenous cytokine levels and spiked with known concentrations of cytokines using 
the Bio-Rad standard containing recombinant cytokines for the 17 different cytokines in 
the kit. The table represents the expected concentration after subtraction of the 
endogenous levels of cytokines  
Spiked concentrations for cytokines in the Bio-Rad 17-plex kit 
  IFN TNF IL-1 IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 
Spike 1 2945.6 2100 4893.8 2754.2 1086.6 8061.7 5348 8532 5000 
Spike 2 406.8 350 978.8 550.8 217.3 1612.3 1069.6 1706 1000 
Spike 3 268.2 175 489.4 275.4 108.7 806 534.8 853 500 
Spike 4 35.6 87.5 48.9 27.5 10.9 80.6 53.5 85 50 
Spike 5 14.6 43.8 9.8 2.8 2.2 16.1 10.7 17 10 
 IL-10  IL-
12p70 
IL-13 IL-17 MCP1 MIP-1 G-CSF GM-
CSF 
 
Spike 1 7516.6 7497.2 1191.4 4321.3 5348 3963.4 3963.4 3963.4  
Spike 2 1503.3 1499.4 238.3 864.3 1069.6 792.7 792.7 792.7  
Spike 3 751.7 749.7 119.1 432.1 534.8 396.3 396.3 396.3  
Spike 4 75.2 75 11.9 43.2 53.5 39.6 39.6 39.6  
Spike 5 15 15 2.4 8.6 10.7 7.9 7.9 7.9  
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Linco human 29-plex assay (study 3) 
A human 29-plex Linco Inc assay (cat no HCYTO -60-K-PMX29) was done according 
to manufacturer’s instructions. Briefly, a standard curve ranging from 3.2 pg/ml to 10 000 
pg/ml was generated by serial dilution of reconstituted standard. Two sets of samples were 
used, as described earlier, with the exception that the Linco Inc standard (provided with the 
kit) was used to spike unstimulated whole blood culture at final concentrations of 5000, 1000, 
500, 50 and 10 pg/ml. The filter plate was blocked by pipetting 200 μl of assay buffer into 
each well. After 10 minutes the assay buffer was discarded by vacuum aspiration and 25 μl of 
assay diluent was added to the wells designated for the samples, while 25 μl of RPMI-1640 
with Glutamax (GIBCO) was added to the wells designated for standards. According to the 
plate layout, 25 μl of either standard or sample was then added to the appropriate wells after 
which 25 μl of antibody coated fluorescent beads was added. Biotinylated secondary 
(detection) and Streptavidin-PE-labelled antibodies were then added to the plate respectively, 
with alternate incubation and washing steps. Finally 100 μl of sheath fluid was added to the 
wells and the plate read immediately on the Bio-plex array reader, at high and low RP1 
targets, using a 5 PL regression curve. 
RnD Systems fluorokine-(MAP) assay using human Base kits A and B (study 3)  
The assay was done according to the manufacturer’s instructions. Briefly, the standard 
curves for the RnD System fluorokine-(MAP) human base kits A (cat # LUH000) and B (cat # 
LUH001) were generated by reconstitution in standard diluent provided with the kit. Samples 
included the same set of antigen-stimulated whole blood culture supernatants used for the Bio-
plex and LINCO-plex assays described earlier, as well as serum (diluted one in four) and 
whole blood supernatant spiked at six different concentrations with recombinant cytokine 
from the RnD System’s standard (Part # 895531, lot # 238222 and Part # 895546, lot # 
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238223 [base kit A] and Part # 892794, lot # 233020 [base kit B], table 2.2). An eight-point 
standard curve, with each cytokine spanning its own unique specific range, was generated and 
50 μl of each standard and sample were added to a 96-well plate containing fluorescent 
antibody coated beads. After alternate incubation and washing steps, detection and PE-
labelled secondary antibodies were added and the plate read on the Bio-plex array reader, at a 
low RP1 target, using a 5 PL regression curve. 
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Table 2.2: Expected Concentrations of Cytokines in the spiked supernatant and 
serum samples (pg/ml) using the RnD assay. Whole blood supernatant and serum 
samples from a healthy control were assessed for endogenous cytokine levels and spiked 
with known concentration of cytokines using recombinant cytokine from the RnD 
Systems fluorokine-(MAP) 13-plex standard containing all 13 cytokines. The table 
represents the expected concentration after subtraction of the endogenous levels of 
cytokines 
Spiked concentrations for cytokines in the RnD Systems MAP Base Kit A 
  IFN-  TNF- IL-1 IL-1r IL-4 IL-6 IL-8 
Spike 1 950 1400 1200 2650 1200 1750 1800 
Spike 2 475 700 600 1325 600 875 900 
Spike 3 237.5 350 300 662.5 300 437.5 450 
Spike 4 118.8 175 150 331.3 150 218.8 225 
Spike 5 59.4 87.5 75 165.6 75 109.4 112.5 
Spike 6 14.8 21.87 18.75 41.4 18.75 27.34 28.12 
Spiked concentrations for cytokines in the RnD Systems 
MAP Base Kit A 
Spiked concentrations for 
cytokines in the RnD Systems 
MAP Base Kit B 
  IL-10 MCP1 MIP-1 MIP-1  IL-12p70 IP 10   
Spike 1 1300 1000 4500 2100 19000 1400   
Spike 2 650 500 2250 1050 9500 700   
Spike 3 325 250 1125 525 4750 350   
Spike 4 162.5 125 562.5 262.5 2375 175   
Spike 5 81.3 62.5 281.3 131.3 1187.5 87.5   
Spike 6 20.31 15.62 70.3 32.81 593.8 21.87   
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RnD Systems Quantikine ELISA (study 3) 
The same M. tuberculosis derived antigens- and PHA-stimulated samples used for the 
Bio-Rad human 17-plex assay (study 3) and Linco human 29-plex assay were also assessed by 
IFN-γ ELISA. The assay was performed as described for the RnD-system Quantikine ELISA 
test 1 as per manuacturer’s instructions. 
Statistics: Bio-plex, Linco-plex and RnD Systems fluorokine-(MAP) assay comparison (Study 
3) 
The correlation between the concentrations of cytokines as measured by the different 
Immunoassays was assessed by the mean of intra-class correlation coefficients and the 
Pearson product-moment correlation coefficient. The analysis was done using STATISTICA 
(version 7). 
2.3 Soluble biomarker analysis 
2.3.1 Serum integrity testing  
Blood samples were taken from all the patients before they were started on anti-tuberculosis 
chemotherapy (diagnosis) and at week 1 in month 1, 2, 3 and 6 after the initiation of 
chemotherapy. Serum was separated by centrifugation (2500 rpm at 4
o
C for 7 min) and 
aliquots of 500 l stored at -80oC until the day of experiment. The samples were collected 
between – give dates- and assays performed in –give month and year. Prior analysis, the 
serum integrity was verified by running the samples on a polyacrylamide one-dimension (1D) 
and two-dimension (2D) gels to confirm that proteins degradation had not occurred. 
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2.3.2 Enzyme-linked immunoassay (ELISA) 
Using ELISA kits from different manufacturers, serum samples were analysed for 
suPAR (Virogate), sICAM-1 (RnD Systems), CRP (Bender MedSytems), LAG-3 (Apotech) 
and Granzyme B (Bender MedSytems). Assays were conducted according to the 
manufacturers’ instructions. Briefly, the method entails that coating antibody (primary 
antibody) against the target protein is adsorbed onto microwell plates. The target protein 
present in the sample binds to antibodies adsorbed to the microwells, and a biotin-conjugated 
secondary antibody specific for the target protein is added and binds to the target protein 
captured by the primary antibody and incubated. After incubation, the unbound biotin-
conjugated secondary antibody is removed in a wash step. Streptavidin-HRP is added and 
binds to the biotin-conjugated antibody. After incubation, unbound Streptavidin-HRP is 
removed during a wash step and substrate solution reactive with HRP is added to the wells. A 
coloured product is formed in proportion to the amount of target protein present in the sample. 
The reaction is terminated by adding acid and absorbance is measured at 450 nm, with 
wavelength correction set at 65 nm. The target protein concentration in the samples is 
determined by plotting their absorption at 450 nm against a standard curve prepared from 
serial dilutions of the recombinant protein of interest. 
2.3.3 Multi-analyte profiling (MAP) assays 
The human death receptors 3-plex (Biosource) and the Cytokines/Chemokines 30-plex 
(LINCO Research Millipore) kits were used for the analysis of soluble TNFRI, TNFRII and 
DR5 levels in a biological context. Assays were conducted according to the manufacturers’ 
instructions. Each bead set was coated with capture antibody specific for one analyte. The 
target protein in the sample binds to the bead-coated antibody. Captured analyte is detected 
using a biotinylated detection antibody and streptavidin-(PE) phycoerythrin and read on the 
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Bio-plex analyser (Bio-Rad), which is a dual laser, flow-based sorting and detection platform. 
One laser is bead-specific and determines which cytokine is being detected. The other laser 
determines the magnitude of the PE-derived signal, which is in direct proportion to the amount 
of analyte bound. 
2.4. Immunophenotyping by flow cytometry 
The immunophenotyping by flow cytometry was performed by Veenstra Hanne from our 
group. This data was used in an attempt to improve the power of the predictive models as it 
was conducted on the same cases as the soluble marker investigations. 
Reagents 
 Fluochrome-labelled monoclonal antibodies (MAb) CD45-PerCP, CD3-PE, CD4-
FITC, CD8-FITC, CD19-FITC, CD56-FITC, and γδTCR-FITC (BD-Pharmingen),  
 Vα24-PE (Beckman Coulter)  
 Saponin (Sigma)  
 Polyethylene glycol 4000 (PEG) (Merck) 
Sodium heparin anti-coagulated whole blood with was washed with phosphate-buffered 
saline (PBS), suspended in 100µL of 0.1% bovine serum albumin (BSA), 0.05% sodium azide 
in PBS and added to the required antibody mixtures. Cells were washed after 20 minutes at 
4°C and red blood cells (RBCs) lysed using cold PBS containing 0.05% saponin, 0.05% 
sodium azide and 3% PEG. Following centrifugation at 700xg the cell pellets were fixed in 
4% formaldehyde in PBS. Samples were analysed using the Becton-Dickinson FACS Calibur 
and CellQuest software. Lymphocytes were gated in a CD45-PerCP versus Side Scatter plot 
(10 000 events in this gate were acquired) and these were further analyzed for expression of 
CD3 and CD4 (or CD8, CD19, CD56, γδTCR) in the FL1 and FL2 channels respectively. The 
lymphocyte sums calculated were all between 95 and 100% (Methods from ‘THE 
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INVESTIGATION OF PERIPHERAL BLOOD CELLULAR IMMUNE RESPONSES 
DURING INFECTION WITH MYCOBACTERIUM TUBERCULOSIS’, PhD thesis by 
Veenstra H, 2006). 
2.5 Gene expression analysis 
2.5.1 Messenger ribonucleic acid (mRNA) extraction and integrity test 
One volume (5 ml) of freshly drawn blood (at diagnosis and week 1 in month 1, 2 and 
6) was added to ten volumes of guanidinium isothiocyanate and triton (GICT)-stabilisation 
reagent (Roche) to achieve cell lysis and stabilisation of the nucleic acids. Nucleic acid-
stabilised blood samples were stored at -80
o
C until the extraction of mRNA 
RNA was isolated from ex vivo blood samples using the mRNA isolation kits for blood 
and bone marrow (Roche). The isolation was done according to the manufacturer’s 
instructions. Magnetic glass particles (MGPs) were added to blood lysate and bound to total 
nucleic acids during incubation. Following incubation, MGPs were separated by 
centrifugation (1100-x g) and unbound elements were removed (by wash). Nucleic acids were 
eluted by incubation in MGP elution buffer, separated from MGPs (using a magnetic 
separator) and transferred into fresh tubes. RNA was then isolated from the total nucleic acids 
by means of biotin-labelled oligo (dT) and streptavidin-coated magnetic particles (SMPs). 
SMPs were separated using a magnetic separator and unbound elements were washed out. 
RNA was eluted in nuclease-free water (Ambion) and concentrated using sodium acetate and 
ethanol. After centrifugation and an ethanol wash in RNase inhibitor superase (Ambion), the 
pellet was resuspended in “RNA secure” (Ambion), which is an RNA suspension solution. 
RNA purity and concentration were assessed using the nanospectrophotometer. RNA integrity 
was verified by reverse transcription of extracted mRNA was into clonal deoxyribonucleic 
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acid (cDNA) and amplification of the -actin gene (Ambion RT-PCR kit). The PCR products 
were run on a 1% agarose gel. 
2.5.2 Reverse transcription of mRNA into clones of deoxyribonucleic acid (cDNA) 
Reverse transcription was carried out with the reverse transcription kit (QIAGEN) 
according to the supplier’s specifications. RNA samples were first incubated in genomic (g)-
wipe-out buffer for two minute at 42
o
C. After gDNA elimination, RNA was reverse 
transcribed using reverse transcriptase, RT buffer and RT primers provided with the kit. 
Reactions took place at 42 
o
C and were inactivated at 95 
o
C. cDNA purity and concentration 
were assessed using a nanospectrophotometer. 
2.5.3 Quantitative real-time PCR 
The expression of genes of interest was quantified relatively using the Light Cycler 
(Roche) and the Quantitec SYBER green polymerase chain reaction (PCR) kit (QIAGEN). 
PCRs were conducted according to the manufacturer’s instructions. The targeted genes were 
IL-4, IL-4δ2, TGF-, TGF-RII, Foxp3 and GATA-3. Primers used for the amplification of 
IL-4* (both IL-4 alternative transcripts) TGF-, TGF-RII, Foxp3 and GATA-3 were 
manufactured by QIAGEN. Because QIAGEN IL-4* primers did not differentiate between IL-
4 and IL-4 splice variant (IL-4δ2) specifically design IL-4 and IL-4δ2 primers were used in an 
additional experiment (119). The sequences of primers used for the amplification of target and 
house keeping genes are in table 2.3. Some manufacturer could not disclose the sequences of 
primers we used to amplify our target genes. Therefore, for these genes, instead of the primers 
sequences the reference sequence identification (RefSeqs-ID) are shown in table 2.3. The 
housekeeping genes used as reference genes for the normalisation of data included -actin 
(QIAGEN primers), GAPDH (Integrated DNA Technology (IDT) primers), HPRT1 (IDT 
primers) and uPO (IDT primers) (table 2.3 for the primers sequences). Although validated 
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primers were used, the amplification efficiency of each primer pair was assessed. This was 
done through a titration series of amplicon from a patient. PCRs consisted of a 20 μl reaction 
including, 10 μl of SYBER green master mix, 2 μl (0.1 μg) of cDNA, 2 μl (05 μM) of primers 
and 6 μl of RNase-free water. Data were analysed using the REST 2005 program from Corbett 
Life Science. 
Table 2.3: Sequences of primers used for the amplification of target and house 
keeping genes. When the primers sequences could not be disclosed by the 
manufacture the code of target genes they amplified were used instead in the table. 
 
(*) = Primers used amplified both IL-4 and IL42 
Targeted genes Primers sequences or Reference sequences ID 
IL-4* NM_000589, NM_172348  
IL-4 Forward: 5’-CGA GTT GAC CGT  AAC AGA CAT-3’; Reverse:5’ CGT CTT TAG 
CCT TTC CAA GAA G-3’ 
IL-4δ2 Forward: 5’-CAG AGC AGA AGA ACA CAA CTG-3’; Reverse: 5’-GTC TTT 
AGC CTT TCC AAG AAG-3’ 
TGF, and  NM_000660 
TGF-RII, NM_003242 
Foxp3 NM_014009 
GATA-3 NM_001002295, NM_002051 
House keeping Genes 
-actin  NM_001101 
GAPDH (1) Forward: 5’-ACC CAC TCC TCC ACC TTT G -3’; Reverse: 5’-CTC TTG TGC 
TCT TGC TGG G -3’ 
GAPDH (2) Forward: 5’-TGA AGG TCG GTG TGA ACG GAT TTG GC -3’; Reverse: 5’-CAT 
GTA GGC CAT GAG GTC CAC CAC -3’ 
HPRT1 Forward: 5’-TGA CAC TGG CAA AAC AATGCA-3’; Reverse: 5’-GGT CCT TTT 
CAC CAG CAA GCT-3’ 
uPO Forward: 5’-GCA ATG TTG CCA GTG TCT GT-3’; Reverse: 5’-GCC TTG ACC 
TTT TCA GCA AG-3’ 
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2.6 Statistical analysis 
The statistical analysis of the results in this thesis was done in collaboration with the 
Stellenbosch University Centre for Statistical Consultation. 
2.6.1 Analysis on soluble biomarker 
All on the soluble markers were done using STATISTICA software version 7. 
Statistical analysis of the immune response between and within groups (slow responders and 
fast responders) at diagnosis, week one, week five, month two and at the end of chemotherapy 
(month six) was done using repeated measures of analysis of variance. The difference between 
the patients and the controls was analysed using one-way ANOVA. The association between 
the immune parameters and the extent of disease was assessed using the Mann Whitney U-
test. A p-value of p < 0.05 was judged significant. The predictive power of selected immune 
markers for sputum culture status at month two was assessed by general discriminant analysis 
(GDA) and support vector machines (SVM).  
2.6.2 Analysis on gene expression 
The differences in targeted mRNA expression between groups and between diagnosis 
and week one after initiation of treatment were analysed using REST 2005 software. REST 
2005 is a strong randomisation test that determines whether there is a significant difference 
between two groups. The program takes into account reaction efficiency and normalisation. 
The program performs 50,000 random reallocations of samples between the two groups, and it 
is based on the principle that: "If any perceived variation between the groups is due only to 
chance, then it will be possible to randomly swap values between the two groups and not see a 
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greater difference than what was initially seen between the groups" (adapted from REST 
2005 manual). 
2.7 Ethics 
All patients involved in the study received and signed a consent form. The study was 
approved by the local health committees representing the people in the areas and the Ethics 
Committee of the Faculty of Health Sciences, Stellenbosch University, the Ethics Committee 
of Tygerberg Hospital and the Head of Health, City of Cape Town. 
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________________________________________________________ 
CHAPTER 3: Evaluation of Cytokine Multiplex Fluorescent Bead-based 
Immunoassays as a Screening Tool for the Search of Biomarkers 
________________________________________________________ 
3.1 Introduction 
Cytokines are important modulators of immune response pathways (120-122). 
Cytokine expression profiling (CEP) has become a popular and established method for the 
identification and characterisation of disease-associated immune responses (123-126). 
Previously, CEP was a laborious process requiring substantial sample volumes when multiple 
cytokines were under investigation. However, CEP methodology has been revolutionised by 
the recent introduction of Luminex technology, a bead based assays allowing the measurement 
of up to 100 different analytes in a 50 µl volume sample (127).  
The reduced sample volume and time-saving advantages of the Luminex system have 
made it an attractive method for large-scale cross-sectional, association or cohort studies 
which investigate the host immune response (128-131). Khan et al. (132) have comparatively 
assessed multiplex kits from LINCO Research, Bio-Rad Laboratories, RnD Systems and 
Biosource International and compared them to an enzyme-linked immunosorbant assay 
(ELISA). The comparison was based on the measurement of a sample of five cytokines 
(serum samples from healthy individuals intravenously injected with endotoxin). They 
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reported that the cytokine concentrations, as measured by the different kits, showed similar 
trends, although the absolute concentrations measured were different.  
There are also a number of reports validating Luminex systems. These studies often 
use the approach of a single sample type, focusing on either serum (132;133), plasma 
(134;135) or culture supernatants (136;137). However, the number of independent published 
articles comparing the performance of different Luminex kits across different sample types is 
limited (138), as limited is the number of cytokines evaluated by the kits. 
The present study not only has the advantage of combining a head-to-head comparison 
of different kits and assays on their ability to measure cytokine levels in different types of 
sample, but is also the first independent study to comparatively assess the recovery of each 
cytokine by the commercially available Bio-Rad 17-plex, LINCO 29-plex and RnD 
Fluorokine-(MAP) base kits A and B (13 cytokines total) with reference to instrument settings 
and calibration. 
3.2 Results 
3.2.1 Bio-Rad human 17-plex assay vs. RnD Quantikine IFN- ELISA (study 1) 
The comparative assessment of IFN- ELISA and IFN- measurements from the Bio-
Rad human 17-plex kit was done using serum and PBMC supernatant samples unspiked and 
spiked at 500 pg/ml (table 3.1). Overall, the ELISA showed better recoveries than Bio-Rad’s 
human 17-plex. No IFN- was detected by either the Bio-Rad assay or the ELISA in the 
unspiked, unstimulated supernatant. The baseline level of IFN-γ in unspiked serum, as 
measured by the ELISA, was nil, whereas the Bio-Rad showed a reading of 257 pg/ml. The 
spiked control recoveries for the ELISA were 117% (control 1) and 116% (control 2) 
compared to 55.9% (control 1) and 31.17 % (control 2) for the Bio-Rad human 17-plex assay. 
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The recoveries of the spiked serum samples were 119.6 % for the ELISA and 30.4 % for Bio-
Rad human 17-plex. IFN- spiked whole blood supernatant, as measured by the ELISA, 
showed a recovery of 121.8%, whereas the Bio-Rad kit recovery was 45.7.5%. The linearity 
of both assays was assessed by measuring the concentration of IFN-γ in undiluted and diluted 
BCG-stimulated PBMC supernatant with a dilution factor of ½. Both assays showed similar 
linearity, with a range of 93.46% to 110%, as measured by ELISA, compared to 70.5% to 
94.43% as measured by the Bio-Rad human 17-plex. 
Stellenbosch University  http://scholar.sun.ac.za
 62 
Table 3.1: IFN-γ based comparison of Bio-Rad human 17-plex and ELISA (RnD 
System). Serum, non-stimulated supernatant and BCG stimulated supernatant from a 
PBMC assay were used to comparatively assess the performance of the Bio-Rad human 
17-plex. Pre-diluted serum and non-stimulated supernatant were spiked at 500pg/ml to 
assess the recovery. The linearity was assessed by measuring the level of IFN-γ in 
undiluted and diluted BCG stimulated culture supernatant.  
 
Samples and controls Spiked at 500 pg/ml Recovery% 
 ELISA Bio-Rad /Bio-plex 
Serum 119.6 30 
WBA 121.8 45.75 
PBMC 113.8 8.76 
Control 1 117 55.9 
Control 2 116 31.17 
BCG stimulated supernatant from PBMC 
assay Linearity study 
Linearity% 
 ELISA Bio-Rad /Bio-plex 
PBMC 1 (healthy volunteer 1) 93.46 94.43 
PBMC 2 (healthy volunteer 2) 110 70.5 
 
3.2.2 Recovery of the Bio-Rad human 17-plex assays (study 2) 
The recovery of the Bio-Rad human 17-plex was assessed using spiked whole blood 
culture supernatants from three healthy individuals and each of the supernatants was spiked at 
three different concentrations (table 3.2). Generally, a lack of accuracy was observed as 
illustrated in table 3.2. At a high RP1 target, 21% of positive readings were in the recovery 
range of 70 to 130%, whereas only 12.4% were within that range when samples were read at a 
low RP1 target. The individual recovery ranges are summarised in table 3.2. 
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Table 3. 2: Bio-Rad human 17-plex expected and observed cytokine concentrations 
and recovery (Study 2). Unstimulated whole blood culture supernatant samples from a 
healthy volunteer were spiked at three different concentrations. Samples were analysed 
on the Bio-plex system instrument and the recovery of each cytokine in the panel 
assessed. In the table are represented the expected concentrations after subtraction of the 
endogenous levels of cytokines 
 
 High RP1 target Low RP1 target 
Expected (pg/ml) 
Observed 
(pg/ml) 
Recovery (%) 
Observed 
(pg/ml) 
Recovery (%) 
IFN-gamma 
 
1797.5 OOR> NA 9316 518.3 
179.7 600.25 334 491.23 273.36 
18.0 40.36 224.2 27.1 150 
TNF-alpha 
 
10351.4 8424.8 81.4 16605.5 160.4 
1035.1 2212 213.7 1582.7 152.9 
103.5 178.7 172.6 138.7 134.0 
 
IL-1beta 
 
3132.0 4082.4 130.3 10131.7 323.5 
313.2 1800.33 574.8 421.8 134.7 
31.3 56.6 180.7 49.4 157.7 
 
IL-2 
 
1762.7 1882.8 106.8 2895.7 164.3 
176.3 363.8 206.4 302.2 171.4 
17.6 40.3 228.7 32.6 185.0 
IL-4 
 
695.4 707.1 101.7 OOR> NA 
69.5 202.8 291.6 164.7 236.8 
7.0 22.2 319.2 15.3 220.0 
IL-5 
 
5159.5 8582.8 166.3 13496 261.6 
516.0 2727.2 528.6 739.7 143.4 
51.6 96.4 186.8 79.5 154.1 
L-6 
 
3422.8 2817 82.3 8190.6 239.3 
342.3 893.2 261.0 550.6 160.9 
34.2 107.9 315.3 60.4 176.5 
IL-7 
5460.6 9190 168.3 10819.1 198.1 
546.1 1392 254.9 1032 189.0 
54.6 145.1 265.8 98.6 180.6 
IL-8 
 
3672.0 3702.8 100.8 5661.5 154.2 
367.2 861.3 234.6 613 166.9 
36.7 89 242.4 39.1 106.5 
IL-10 
 
4810.6 4540.7 94.4 7128.86 148.2 
481.1 1348.9 280.4 732.23 152.2 
48.1 98.43 204.6 75.53 157.0 
IL-12-p70 
 
4798.2 4641.6 96.7 88036 1834.8 
479.8 1191.7 248.4 942 196.3 
48.0 114 237.6 68.4 142.6 
IL-13 
 
762.5 1116.1 146.4 1401 183.7 
76.3 169.7 222.6 140.1 183.7 
7.6 15.7 205.8 14.1 184.8 
IL-17 
 
2765.6 3074.8 111.2 9773.8 353.4 
276.6 940.6 340.1 791.9 286.3 
27.7 110.2 398.4 70.6 255.2 
GM-CSF 
 
2552.7 4100.5 160.6 4716.7 184.8 
255.3 597.3 234.0 478.6 187.5 
25.5 55.1 215.8 42 164.5 
G-CSF 
 
2536.6 21494.94 847.4 3861 152.2 
253.7 564.8 222.7 431.6 170.1 
25.4 50.1 197.5 40.2 158.5 
MCP-1 
 
3412.6 5958.1 174.6 7755.5 227.3 
341.3 700.5 205.3 595.1 174.4 
34.1 16.7 48.9 7.5 22.0 
MIP-beta 
 
2544.7 1962.6 77.1 6157.1 242.0 
254.5 636.56 250.2 382.1 150.2 
25.4 47.5 186.7 44.9 176.4 
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3. 2. 3 Bio-Rad human 17-plex, LINCO 29-plex and RnD Systems MAP base kit A and B 
recoveries study and comparison. 
3.2.3.1 Bio-Rad human 17-plex assay (test 3) 
In this study, recovery of the Bio-Rad human 17-plex was assessed for five different 
concentrations of individual cytokines. Fluorescence was read both at high and low RP1 
targets, with 85 readings made for each RP1 target. A total of 65 readings out of 85 were 
positive for the low RP1 target (see Figure 3.1), with 54% of these positive readings (41.2% of 
the total readings) falling within the acceptable recovery range of 70 to 130%. There were 62 
positive readings out of 85 at the high RP1 target, with 61% of these (44.7% of the total 
readings) falling within the acceptable recovery range of 70 to 130%. The cytokines IFN-γ, 
TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-12p70, IL-13, IL-17, GM-CSF and MCP-1 measured 
most accurately when samples were read at the high RP1 target, whereas measurements of IL-
5, IL-10, G-CSF and MIP-1β showed better recoveries when samples were read at a low RP1 
target. Interfering interactions in the samples presumably led to falsely increased, and signal 
inhibition for, IL-8 detection, which resulted in out-of-range readings for four out of the five 
assessed concentrations. The recoveries of the individual cytokines included in the Bio-Rad 
human 17-plex panel are shown in Figure 3.2. 
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A B
C
 
Figure 3.1. The total, positive and out of range readings for Bio-Rad’s human 17-
plex, LINCO’s 29-plex and RnD-System’s MAP 13-plex assays. Total reads or 
readings, positive reads (reads that gave a concentration within the standard curve range) 
and out of range reads are illustrated. (A): Bio-Rad 17-plex kit total, positive and out of 
range readings. Un-stimulated whole blood culture supernatants from a healthy donor 
was spiked at 5 different concentrations ranging from 8532-2.2pg/ml with standard 
containing the 17 different recombinant cytokines from the Bio-Rad kit. Samples were 
then read on the Bio-plex instrument at low and high RP1 targets. (B) LINCO 29-plex 
kit total, positive and out of range readings. Un-stimulated whole blood culture 
supernatants from a healthy donor were spiked at 5 different concentrations ranging 
from 5000-10 pg/ml with standard containing the 29 different recombinant cytokines 
from the LINCO-Inc kit. Samples were then read on the Bio-plex instrument at low and 
high RP1 targets. (C) RnD Systems MAP 13-plex kit’s total, positive and out of range 
readings. Un-stimulated whole blood culture supernatant and serum from a healthy 
donor were spiked at 5 or 6 different concentrations ranging from 2650-14.8 pg/ml with 
standard from the 13 different recombinant cytokines from the RnD System’s base kits 
A and B. Samples were then read on the Bio-plex instrument at low RP1 targets. 
Low RP1 
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Figure 3.2. Recoveries of the Bio-Rad 17-plex assay (study 3). Un-stimulated 
whole blood culture supernatant samples from a healthy donor were spiked at 
five different concentrations (8532-2.2 pg/ml) with the standard from Bio-Rad 
17-plex kit. Samples were assayed in duplicate and read at high and low RP1 
targets on the Bio-plex system instrument. Recoveries were calculated for each 
of the cytokines in the panels for each of the spiked concentrations. The Figure 
shows the best recovery obtained for each individual cytokine. 
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3.2.3.2 LINCO human 29-plex assay 
The recovery of the cytokines forming part of the LINCO-Inc 29-plex panel were 
assessed at five different concentrations (5 000, 1 000, 500, 50 and 10 pg/ml), and read at high 
and low RP1 targets. The test showed an acceptable performance. A total of 145 readings 
were made at each RP1 target and 123 of these fell within the detection range when read at 
high RP1, compared to 136 out of 145 when read at the low RP1 target (Figure 3.1). Of the 
positive readings, 78.4% (66.2% of the total readings) read at the high RP1 target had 
recoveries falling within the acceptable range of 70 to 130%, whereas approximately 70% of 
positive readings (65.7% of the total readings) made at a low RP1 target achieved this 
acceptable recovery. Measurements of IFN-, IL-1, IL-4, IL-6, IL-7, IP-10, MCP-1 and G-
CSF were found to be most accurate when the plate was read at a high RP1 target, with 
recoveries falling between 70 to 130%, whereas those for TNF-, IL- IL-1r, IL-2, IL-5, 
IL-10, IL-12p40, IL-12p70, IL-13, Fractalkine, MIP-1, MIP-1, GM-CSF, TGF-, sCD40L, 
VEGF, Eotaxine and EGF were most accurate when read at a low RP1 target . IL-15 and IL-
17 showed similar recoveries at both high and low RP1 targets. The level of false signal was 
very high for IL-8. The coefficients of variation between the measurement at high RP1 and 
low RP1 targets were less than 5% when applicable (when both high and low RP1 showed 
positive readings). The recoveries of the individual cytokines included in the LINCO 29-plex 
panel are shown in Figure 3.3. 
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Figure 3.3: Recoveries of the LINCO 29-plex assay. Un-stimulated whole blood 
culture supernatant samples from a healthy donor were spiked at five different 
concentrations ranging from 5000-10pg/ml with the standards from the LINCO 29-plex 
kit. Samples were assayed in duplicate and read at high and low RP1 targets on the Bio-
plex system instrument. Recoveries were calculated for each of the cytokines in the 
panels for each of the spiked concentrations. The Figure shows the best recovery 
obtained for each individual cytokine. 
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3.2.3.3 RnD Systems Fluorokine-MAP assay 
The recoveries of 13 cytokines measured in whole blood culture supernatant and 
serum samples were assessed at six different concentrations (Table 2.2 Material and Methods 
section using the RnD Systems Fluorokine-MAP assay. A total of 78 readings were made 
using whole blood culture supernatant and 67 from serum samples. All whole blood 
supernatant and serum sample readings were positive and within the standard curve range 
(Figure 3.1). A total of 67% of whole blood supernatant samples achieved recoveries within 
70 to 130%, compared to approximately 56% of the serum samples. Details of individual 
cytokine recoveries are shown in Figure 3.4. The recoveries of control spiked standard 
diluents ranged from 53.3% to 103.8% for whole blood supernatant samples and from 66.5% 
to 130% for serum samples. 
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Figure 3.4: Recoveries of RnD System’s Fluorokine-MAP 13-plex base kits A and B. 
(A) Un-stimulated whole blood culture supernatant samples from a healthy donor were 
spiked at six different concentrations (2650-29.7 pg/ml) with the standards from RnD-
System Fluorokine-MAP base kits A and B. Samples were assayed in duplicate, read at a 
low RP1 target on the Bio-plex system instrument and recoveries calculated for each of 
the cytokines in the panel. The Figure shows the individual cytokine’s best recovery 
obtained. (B) Serum samples from a healthy donor were spiked at five or six different 
concentrations (2650-43.8 pg/ml) with the standards from RnD-System’s Fluorokine-MAP 
base kits A and B. Samples were assayed in duplicate, read at a low RP1 target on the Bio-
plex system instrument and recoveries calculated for each of the cytokines in the panel. 
The Figure shows the individual cytokine’s best recovery obtained. 
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3.2.3.4 RnD Systems ELISA 
The RnD System’s IFN- ELISA was used as a gold standard against which the 
different luminex kits where compared for their reliability in measuring cytokine 
concentrations in biological samples. The ELISA was chosen as a golden standard standard 
due to the very good recovery values achieved with this kit (table 3.1). Samples tested 
included antigen-stimulated samples with their negative and positive controls. As expected, 
the negative control showed a very low level of IFN- whereas the positive control and 
antigen-stimulated samples showed higher levels of IFN- (table 3.2). 
3.2.3.5 Bio-Rad 17-plex, LINCO 29-plex, RnD Systems Fluorokine-MAP and RnD Systems 
ELISA: IFN--based comparison 
The concentration of IFN- as measured in stimulated whole blood culture supernatant 
by the LINCO-plex assay, RnD Systems Fluorokine-MAP assay and RnD Systems ELISA, 
followed the same trend. In general, poor correlations were observed between the Bio-Rad 17-
plex assay and the other assays (table 3.3 and Figure 3.5.). The intra-class correlation 
coefficients (ICC) of agreement and the Pearson product-moment correlation coefficient (r) 
between the different luminex kits and the RnD Systems ELISA were respectively 0.64 (ICC) 
and 0.75 (r) for the correlation between LINCO 29-plex and RnD Systems ELISA., The 
correlation analysis between RnD Systems Fluorokine-MAP/RnD Systems ELISA gave an 
ICC of agreement of 0.1 and a Pearson correlation coefficient (r) of 0.99. Whereas the 
analysis of the correlation between the Bio-Rad 17-plex kit and the RnD Systems ELISA 
measurement gave an ICC of agreement of -0.01 and a Pearson correlation coefficient (r) of -
0.09 and The correlation between the different luminex kit measurements for the cytokines 
present in the three kit panels is shown in table 3.4. 
Stellenbosch University  http://scholar.sun.ac.za
 72 
Table 3.3. IFN-γ-based comparison of ELISA, LINCO 29-plex, Bio-Rad human 17-plex 
and RnD Systems Fluorokine-MAP assays. Supernatant was generated using whole blood 
from a healthy subjects (1-5) in six-day assays stimulated with eight different antigens and a 
phytohaemagglutinin (PHA)-stimulated positive control. 
 
 
RnD 
Systems 
ELISA 
(pg/ml) 
LINCO 29-plex 
(pg/ml) 
Bio-Rad human 
17-plex (pg/ml) 
RnD Systems 
Fluorokine-
MAP (pg/ml) 
Whole blood supernatant     
PHA-stimulated 1731.38 451.56 64.7 86.83 
Negative control 0 1.39 0 0 
ESAT-CFP-10 (1) 1181.6 969.12 undetected Not measured 
ESAT-CFP-10 (2) 908.83 950.62 2.14 Not measured 
ESAT-6 (2) 839.42 536.92 193.53 Not measured 
RV1115 (4) 489.1 247 49.08 30.26 
ESAT-6 (3) 235.67 125.97 104.94 17.65 
TB10.4 (5) 118.9 133.82 172.19 Not measured 
RV1115 (3) 57.5 55.63 undetected 1.56 
RV1073 (5) 23.78 0.44 99.2 0.28 
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Figure 3.5: IFN-γ-based correlation between ELISA, LINCO 29-plex, Bio-Rad 
17-plex and RnD Systems Fluorokine-MAP-13-plex assays. IFN- concentration 
was measured in stimulated whole blood culture supernatant using the LINCO 29-
plex assay, RnD Systems Fluorokine-MAP-13-plex assay, Bio-Rad 17-plex assay 
and RnD Systems IFN-γ ELISA. (A) Scartterplot of the correlation between the 
LINCO 29-plex assay and RnD Systems ELISA. A positive correlation was observed 
between LINCO 29-plex assay and RnD Systems ELISA (r = 0.75; ICC of 
agreement = 0.64). (B) Scartterplot of the correlation between the RnD Systems 
Fluorokine-MAP 13-plex assay and RnD Systems ELISA. A positive correlation was 
observed between RnD Systems Fluorokine-MAP and RnD Systems ELISA (r = 
0.99; ICC of agreement = 0.1). (C) Scartterplot of the correlation between the Bio-
Rad 17-plex assay and RnD Systems ELISA. A negative correlation was observed 
between the Bio-Rad 17-plex assay and RnD Systems ELISA (r = - 0.09; ICC of 
agreement = - 0.01). 
 
Stellenbosch University  http://scholar.sun.ac.za
 74 
Table 3.4: Correlation between ELISA, LINCO 29-plex, Bio-Rad 17-plex and RnD 
Systems Fluorokine-MAP 13-plex assays. Whole blood from a healthy donor were 
stimulated with M. tuberculosis derived antigens and with phytohaemagglutinin (PHA) 
control in six day assays. The table shows the intra-class correlation coefficients (ICC) of 
agreement and consistency as well as Pearson correlation coefficients (r) between 
measurements obtained with the different luminex kits and the ELISA. 
  Rater 1 Rater 2 ICC agreement ICC consistency r 
IFN 
RnD System ELISA LINCO 29-plex 0.638 0.67 0.75 
RnD System ELISA Bio-Rad 17-plex -0.014 -0.02 -0.1 
RnD System ELISA RnD-System MAP 0.1 0.1 0.99 
LINCO 29-plex Bio-Rad 17-plex -0.06 -0.085 -0.2 
LINCO 29-plex RnD-System MAP 0.26 0.36 0.97 
Bio-Rad 17-plex RnD-System MAP 0.18 0.21 0.22 
IL-2 LINCO 29-plex Bio-Rad 17-plex 0.56 0.65 0.71 
IL-4 
LINCO 29-plex Bio-Rad 17-plex 0.098 0.17 0.23 
LINCO 29-plex RnD-System MAP -0.005 -0.01 -0.3 
Bio-Rad 17-plex RnD-System MAP 0.002 0.0064 0.23 
IL-6 
LINCO 29-plex Bio-Rad 17-plex -0.05 -0.07 -0.1 
LINCO 29-plex RnD-System MAP 0.77 0.74 0.88 
Bio-Rad 17-plex RnD-System MAP -0.08 -0.075 -0.1 
IL-8 
LINCO 29-plex Bio-Rad 17-plex 0.017 0.03 0.04 
LINCO 29-plex RnD-System MAP 0.3 0.56 0.73 
Bio-Rad 17-plex RnD-System MAP -0.046 -0.042 -0 
IL-10 
LINCO 29-plex Bio-Rad 17-plex -0.02 -0.02 -0 
LINCO 29-plex RnD-System MAP 0.007 0.014 0.68 
Bio-Rad 17-plex RnD-System MAP 0.004 0.007 0.45 
GM-CFS LINCO 29-plex Bio-Rad 17-plex -0.014 -0.021 -0.2 
TNF- 
LINCO 29-plex Bio-Rad 17-plex -0.06 -0.067 -0.1 
LINCO 29-plex RnD-System MAP 0.9 0.9 0.91 
Bio-Rad 17-plex RnD-System MAP 0.42 0.38 0.38 
IL-1 LINCO 29-plex Bio-Rad 17-plex -0.27 -0.27 -0.3 
IL-5 
LINCO 29-plex Bio-Rad 17-plex -0.1 -0.093 -0.1 
LINCO 29-plex RnD-System MAP -0.046 -0.038 -0.1 
Bio-Rad 17-plex RnD-System MAP -0.18 -0.15 -0.5 
IL-13 LINCO 29-plex Bio-Rad 17-plex -0.14 -0.138 -0.2 
IL-17 LINCO 29-plex Bio-Rad 17-plex -0.1 -0.11 -0.2 
MCP-1 
(MCAF) 
LINCO 29-plex Bio-Rad 17-plex 0.5 0.48 0.48 
LINCO 29-plex RnD-System MAP  0.02 0.043 0.62 
Bio-Rad 17-plex RnD-System MAP -0.008 -0.018 -0.2 
MIP-1 
LINCO 29-plex Bio-Rad 17-plex 0.04 0.037 0.05 
LINCO 29-plex RnD-System MAP 0.25 0.25 0.73 
Bio-Rad 17-plex RnD-System MAP 0.27 0.26 0.43 
MIP-1 LINCO 29-plex RnD-System MAP 0.72 0.78 0.95 
IL-7 LINCO 29-plex Bio-Rad 17-plex 0.11 0.25 0.36 
IL-12 LINCO 29-plex Bio-Rad 17-plex -0.16 -0.14 -0.1 
G-CSF LINCO 29-plex Bio-Rad 17-plex 0.004 0.005 0.01 
IL1- LINCO 29-plex RnD-System MAP 0.33 0.49 0.97 
IL-1r LINCO 29-plex RnD-System MAP 0.23 0.39 0.85 
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3.3 Discussion 
This study evaluated three commercially available cytokine multiplex bead 
immunoassays from Bio-Rad, LINCO Inc and RnD Systems. The results suggest that, for the 
particular samples tested in this study, the LINCO Inc human 29-plex and the RnD Systems 
Fluorokine-MAP assays were the most accurate for the measurement of cytokine 
concentrations in whole blood culture supernatant and achieved good recovery ranges for 
most cytokines whereas the performance of the Bio-Rad human 17-plex assay was 
suboptimal. 
The first comparative study, between the Bio-Rad human 17-plex assay and RnD 
Systems ELISA, was based on the measurement of IFN- in spiked samples (serum and 
supernatant) and revealed that the recovery achievable by the Bio-Rad human 17-plex assay 
kit was less than half of that obtained by the ELISA. Further comparison, including the Bio-
Rad human 17-plex assay, LINCO 29-plex assay, RnD Systems Fluorokine-MAP assay and 
ELISA, was made based on IFN- responses in antigen-stimulated whole blood culture 
supernatant. It was found that all assays were capable of differentiating the positive and 
negative controls. Moreover, they were able to efficiently pick up the antigens’ specific IFN- 
response when applicable, with the exception of the Bio-Rad human 17-plex assay, where 
IFN- levels in two of the antigen-stimulated samples (ESAT-CFP-10 and Rv1115) went 
undetected. 
Concentrations of IFN- measured by the LINCO 29-plex assay, RnD Systems 
Fluorokine-MAP assay and ELISA seemed to be correlated, but results obtained using the 
Bio-plex assay correlated poorly with values obtained using the other three assays. This 
contradicts a study by Khan et al. (132), who showed that cytokine levels measured by the 
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Bio-plex assay have similar trends to the LINCO-plex and ELISA measurements. Very similar 
to the findings by DuPont et al. (139) was a very strong correlation between the level of IFN- 
measured by ELISA and the LINCO-plex kit in whole blood culture supernatant found in this 
study. 
Although recoveries should ideally not fall outside the acceptable range, this can be 
considered useable if the recovery remains constant across different sample types and 
dilutions. This was not the case when measuring cytokines using the Bio-Rad kits used during 
this study. Therefore it would be impossible to compensate for any inaccuracy evident in any 
one sample matrix. Discrepancies observed using the Bio-plex kits may be partly explained by 
the presence of interfering proteins such as heterophilic antibodies (140;141). De Jager et al. 
(142) have described methods to avoid heterophilic antibody interference in plasma and 
synovial fluid that improved the performance of the multiplex immunoassay. However, any 
manipulation of samples in clinical studies is not necessarily advantageous due to possible 
unforeseen effects on the results. The fact that LINCO Inc and RnD Systems kits had 
reasonable accuracy in this study suggests that other mechanisms may play a role in the Bio-
Rad test kit. 
It will therefore be wise to perform careful optimisation and validation of any 
commercial multiplex cytokine assays prior to large-scale clinical studies, as the quality 
controls supplied with the kits to measure standard curve integrity can only guarantee the 
accuracy or sensitivity of the assay if they are reconstituted and measured in the same matrix 
type as the samples investigated. Matrix effects appear to play a major role in assay 
performance and the type of sample tested may therefore have serious effects on assay 
performance. It is clear that the theoretical capabilities of this new technology cannot be fully 
achieved in practice (134). Researchers using these kits should include replicates of samples 
as well as negative and positive (low, medium and high) controls with known concentrations 
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of the cytokines of interest to be confident about the results obtained. Furthermore, controls 
should be included that reflect both the diluents used to reconstitute the standard supplied with 
the kit and the sample matrix tested in order to account for possible matrix effects. This will 
allow the assessment of linearity and recovery and aid in the choice of best standard curve 
regression and optimal calibration (143). 
3.5 Conclusion 
In conclusion, the most appropriate use for multiplex cytokine assays currently would 
be as a screening tool, for the selection of candidate biomarkers characteristic of disease-
associated immune responses. Promising candidates can then be validated using a method that 
has been proven reliable, such as high-sensitivity ELISAs. 
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________________________________________________________ 
CHAPTER 4: Sample integrity 
________________________________________________________ 
4.1 Introduction 
Sample integrity is a very critical factor for the reliability of biological test results. 
Considering that the samples to be used for this study had been stored for almost four years, it 
was essential to assess serum for protein integrity and ex vivo blood for presence of non-
degraded mRNA. 
4.2 Study design 
Ex vivo blood samples from TB patients who had been excluded from the study due to 
non-compliance or presence of drug resistant isolates and of whom the serum and nucleic 
acids had been stored and stabilised exactly like the samples for the main study and for the 
same period were randomly selected and tested for protein and mRNA integrity. 
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4.3 Results and discussion 
4.3.1 Serum  
Serum samples were run on polyacrylamide one-dimension (1D) and two-dimension 
(2D) gels. The gels showed no smear, indicating that the proteins had not been degraded (see 
Figures 4.1 and 4.2) and that the samples were fit for protein analysis. 
Sample 9 diag 9 week4        27 diag 27 week4
5µl       2µl       5µl      2µl    5µl    2µl      5µl     2µl
 
Figure 4.1: Coomassie-stained 1D SDS-PAGE gel of the serum protein from TB 
patients in the study. 
No smear is observed on the gel image, thus protein degradation had not occurred. 
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Sample 27, week 4
Sample 9, diagnosis Sample 9, week 4
Silver-stained 2D gels
14.4 kDa
Sample 27, diagnosis
97.4 kDa
31.6 kDa
21.5 kDa
66.2 kDa
45 kDa
 
Figure 4.2: Silver-stained 2D gels of the serum protein from TB patients in the study. 
No smear is observed on gel image, thus protein degradation had not occurred. 
 
 
4.3.2 Nucleic acid-stabilised ex vivo blood 
Extracted mRNA from frozen blood was converted into clonal deoxyribonucleic acid 
(cDNA) and the housekeeping gene (-actin) was amplified (RT-PCR). The PCR products 
were run on a 1% agarose gel. This gel showed clear amplification of the gene, revealing 
mRNA of a good quality (see Figure 4.3). 
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Figure 4.3: 1% agarose gel of RT-PCR product of mRNA from TB patients in the study. 
The -actin gene was nicely amplified in the test samples, revealing the integrity of the 
mRNA. 
4.4 Conclusion  
The assessment of the integrity of the serum- and nucleic acid-stabilised ex vivo blood 
samples showed that samples were still of a good quality and reliable for proteomic and 
transcriptomic studies respectively. 
100 bp DNA 
Ladder 
(Marker) 
Month 6 
sample 
Week 2 
sample 
No template control 
 primer +enzyme 
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________________________________________________________ 
CHAPTER 5: Evaluation of Biomarkers in a Biological Context as Measures of 
Efficacy and Prognostic Tools in Early Response During Anti-tuberculosis 
Treatment 
Part 1: Soluble Immune Markers 
________________________________________________________ 
Declaration  
The information contained in this chapter was presented as an oral presentation at the 5
th
 
European Congress on Tropical Medicine and International Health and the Abstract was 
published in the European Journal of Tropical Medicine and International Health.  
Reference: J.F. DJOBA SIAWAYA
*
, N.B. Bapela, H. Veenstra, M. Kidd, N. Beyers, P. van 
Helden and G. Walzl. Combined Immune Parameters and X-Ray Data in Early Prognosis 
of Month 2 Sputum Culture Conversion. European Journal Tropical Medicine and 
International Health. Abstract O27-07, Volume 12, Supplement 1, May 2007. 
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5.1 Introduction 
Directly observed treatment short course (DOTS) is currently the most effective means 
of combating tuberculosis (TB)(144-146) and consists of a six month drug regimen divided 
into a four-drug intensive phase of two months, followed by a two-drug continuation phase of 
four months (147). The International Union Against Tuberculosis and Lung Disease 
(IUATLD) recommends sputum smear or culture status after two months of treatment to 
evaluate early response to chemotherapy (62). The implications of failure of sputum 
conversion at this time point include a continuation of the intensive phase and sputum culture 
with drug sensitivity testing to exclude drug resistance, which is not part of routine 
management in many national TB control programs in developing countries due to cost 
implications. However, a two month waiting period before the first indications of treatment 
efficacy is very long and has implications for individual patients, control programs and 
clinical trials of new drugs. Moreover, the bacteria have time to adapt and develop drug 
tolerance(148) and resistance(149;150) during ineffective therapy.  
The overall duration of therapy may adversely affect patient adherence to treatment 
and places a serious strain on healthcare systems in developing countries, as they struggle to 
afford full implementation of the recommended treatment programme. Current literature 
suggests that it may be possible not only to identify patients who require longer than six-
month TB treatment regimens in order to prevent recurrence, but to identify the majority of 
patients who would require a standard antibiotic treatment course (47;64). Stratification of TB 
patients at the time of diagnosis or shortly after the start of treatment into risk groups for 
treatment response, including relapse, might enable TB programmes to concentrate their 
efforts on ensuring strict adherence to shorter (three to four months) treatment regimens in 
many patients and to reserve longer treatment options for those with a higher risk of relapse. 
Such markers may also decrease the required sample size of clinical trials by ensuring equality 
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across treatment arms and would thereby facilitate the development and validation of new 
therapeutic strategies. Markers of treatment effect may also have a major impact on clinical 
trials of new drugs as they would shorten the duration of such trials. 
Cavitatory lung disease at diagnosis and a positive sputum culture at the end of the 
intensive phase of treatment have been shown to characterize patients at high risk for 
treatment failure or relapse (52;53). However, the equipment and skills to perform 
radiological grading of the extent of disease is not universally available in areas with a high 
TB prevalence and the delay after start of treatment before month two sputum culture results 
become available decrease the usefulness of these markers. Markers that are measurable by 
simple tests like ELISA and that correlate with i) the extent of pulmonary TB disease and ii) 
predict the intensive phase treatment outcome as early as possible would therefore have 
significant advantages.  
Only a few studies have focused on immune correlates for early identification of slow 
and fast responders during the course of anti-TB chemotherapy. Veenstra et al.(151) and 
Brahmbhatt et al.(152) demonstrated that immune parameters could be integrated in 
mathematical models for the early prediction of week eight sputum culture conversion. The 
present study follows the same approach by investigating the relationship between host 
marker expression and radiological extent of disease and examines the predictive value of host 
immune parameters on week eight sputum culture conversion. These parameters were selected 
from the literature and are chosen for their biological context (34;79;81;82;93;153-155). We 
show that individual markers correlate with the radiological extent of disease and a 
combination of markers has a high predictive ability for month two treatment response. 
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5.2 Study design 
The sampled population consisted of 20 active TB patients. After the intensive phase 
of chemotherapy (two months), the sputum smear test identified 14 fast responders (sputum 
smear negative) and six slow responders (sputum smear positive), whereas the Bactec sputum 
culture pointed out eight fast responders (sputum culture smear negative) and 12 slow 
responders (sputum culture positive). It was decided to use the Bactec sputum culture status at 
month two as the end point for sputum sterilisation and early response to chemotherapy, as 
sputum culture is currently the most sensitive method for the identification of M. tuberculosis 
in sputum (156). The parameters under investigation included sICAM, CRP, suPAR, LAG-3, 
granzyme B, sTNFRs, DR5 and CD3
dim
/CD56
+
 NKT cells, previously described by Veenstra 
et al. (151). sICAM, CRP, suPAR, LAG-3, Granzyme B, sTNFRs and DR5 were screened for 
surrogates of extent of disease. In addition, the parameters were combined in logarithmic 
model for the prediction of the outcome of the intensive phase of treatment. 
Study flow diagram 
Therapy week 5
Therapy week 1 
Fast responders
(8)
Slow responders
(12)
Identification 
of biomarkers 
of treatment 
response
Identification 
of biomarkers 
of treatment 
response
Therapy week 8
Therapy week 13
Patients at diagnosis (20)
Identification of Biomarkers of disease extent
Therapy week 26
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5.3 Results  
5.3.1 Chest X-ray radiography 
Chest X-rays revealed the presence of cavities in 19 of the 20 patients investigated; 14 
patients had multiple cavities; nine patients had cavity sizes above 4 mm and 11 patients 
below 4 mm; seven patients showed bilateral and 11 unilateral disease; 11 patients had 
radiologically extensive disease (greater that a single apical lobe segment). 
Cavity distribution and alveolar disease distribution among slow and fast responders to 
therapy 
A total of 67% of the slow responders and 75% of the fast responders had multiple 
cavities; 50% of the slow responders and 37% of the fast responders had extensive alveolar 
disease. 58% of the slow responders and 25% of the fast responders had cavities with a size 
greater than 4 mm (Figure 5.1). 
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Figure 5.1. Characteristics of cavities and extent of pulmonary infiltrates in 
slow and fast responders to early tuberculosis treatment. Chest x-rays were 
taken between -2 or +2 months of diagnosis with smear positive pulmonary 
tuberculosis and were blindly analysed for cavities and extent of alveolar disease. 
The % of slow and fast responders presenting with key radiological findings is 
shown. RUL: right upper lobe as reference area for total extent of radiological 
involvement. 
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5.3.2 Immune parameter profiles at diagnosis and extent of pulmonary TB disease 
The concentration of suPAR, sICAM, CRP, LAG-3, granzyme B, sTNFRs and DR5 
were measured in all patients at diagnosis and correlated with radiological extent of disease. 
The association between immune parameters and chest x-ray grading was assessed using the 
Mann Whitney test. The significant findings are shown in Figure 5.2. High levels of CRP at 
diagnosis were found to be associated with the presence of multiple cavities (p≤ 0.05). The 
concentration of suPAR and sICAM-1 at diagnosis were significantly higher in patients with 
extensive alveolar disease (p≤ 0.05). Patients with cavity sizes greater than 4mm had 
significantly higher concentrations of granzyme B (p< 0.01) and sLAG-3 (p< 0.05) at 
diagnosis compared to patients with cavity sizes of less than 4mm. No significant associations 
were found between the markers sTNFRs and DR5 and radiological grading. 
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Figure 5.2: Serum level of CRP, sICAM-1, suPAR, Granzyme B and sLAG-3 in patients 
with different TB disease presentation on chest-x-ray radiography. Chest x-rays were taken 
between -2 or +2 months of diagnosis with smear positive pulmonary tuberculosis and were 
blindly analysed for cavities and extent of alveolar disease. (A) Serum levels of CRP at diagnosis 
is shown in TB patients with and without the presence of multiple cavities on chest x-rays. (B) 
Serum levels of sICAM-1 at diagnosis and (C) serum levels of suPAR at diagnosis are shown in TB 
patients with radiological extent of disease ≤ and > RUL., (D) Serum levels of granzyme B and (E) 
serum levels of sLAG-3 at diagnosis were measured in TB patients with cavity sizes ≤ and > than 
4mm., RUL: right upper lobe (single apical lobe segment) as reference area for total extent of 
radiological involvement. 
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5.3.3 Profile of fast and slow responders for selected immune parameters 
suPAR 
Both fast and slow responders had significantly higher levels of suPAR at diagnosis 
compared to controls (p-value ≤ 0.0005) (Figure 5.3a). Anti-tuberculous treatment 
significantly modulates the levels of suPAR. No significant differences were found between 
patients of either group and controls at the end of treatment (Figure 5.2a). The modulation of 
suPAR in fast and slow responders during therapy followed the same pattern (Figure 5.3a) and 
no statistically significant differences were observed between fast and slow responders during 
the course of therapy. In patients of both groups suPAR concentration decreased significantly 
after one week of treatment (p-value ≤ 0.05) and by the end of treatment were not different 
from control levels (Figure 5.3a). 
sICAM-1 
Both fast and slow responders had significantly higher levels of sICAM at diagnosis 
compared to controls (p ≤ 0.0005) (Figure 5.3b). sICAM-1 concentrations showed little 
change in both groups until the thirteenth week of treatment and only declined at the end of 
treatment where the differences between patients and controls were no longer significant 
(Figure 5.3b). Direct comparison of fast and slow responders showed no significant 
differences (Figure 5.3b). By the end of treatment, only slow responders presented with a 
significant lower sICAM-1 level compared to diagnosis (p ≤ 0.0001) (Figure 5.3b). 
CRP 
Both fast and slow responders had significantly higher levels of CRP at diagnosis 
compared to controls (p ≤ 0.005) (Figure 5.3c). After initiation of treatment (week one, five 
and thirteen) and at the end of treatment no significant differences were found between 
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patients and controls (Figure 5.3c). In patients of both groups, CRP dropped and was 
significantly lower at week one, week five, week thirteen and at the end of treatment when 
compared to levels at diagnosis in the same responder group (p ≤ 0.0005) (Figure 5.3c). 
sLAG-3 
Concentrations of sLAG-3 were not significantly different in patients compared to 
controls at diagnosis; at week five the level of sLAG-3 in fast responders dropped below 
control levels, (p ≤ 0.005) (Figure 5.3d). By week thirteen, both fast and slow responders had 
significantly lower concentrations of LAG-3 compared to controls Fast and slow responders 
had similar level of sLAG-3 at the end of treatment to controls (Figure 5.3d). No significant 
differences were observed in sLAG-3 profiles between fast and slow responders. At the end of 
treatment sLAG-3 increased in both responder groups to the levels seen at diagnosis (Figure 
5.3d). 
Granzyme B 
No difference was seen in the levels of granzyme B between either responder groups at 
any time point and controls (Figure5. 3e). Slow responders had higher concentrations of 
granzyme B than fast responders throughout treatment but the differences did not reach 
statistical significance (Figure 5.3e). In all patients, granzyme B concentrations remained 
relatively constant during the intensive phase of therapy and declined at treatment end (Figure 
5.3e). 
sTNFRI 
No significant changes were seen between fast responders, slow responders and 
controls for the concentrations of sTNFRI at any time point (Figure 5.3f) and there were no 
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significant differences between responder groups. In fast responders, TNFRI concentrations 
were significantly higher at week one (W1) than at diagnosis (p ≤ 0.005) (Figure 5.3f). 
sTNFRII 
Fast responders presented with significantly higher levels of sTNFRII than controls 
throughout treatment (p ≤ 0.005) except at week thirteen. No significant differences were 
observed between slow responders and controls. Fast responders had higher TNFRII 
concentrations throughout treatment than slow responders but the difference observed did not 
reach statistical significance (Figure 5.3g). 
DR5 
sDR5 levels were very low to undetectable in both fast and slow responders at 
diagnosis. Controls had significantly higher concentrations of sDR5 than patients at diagnosis 
(p ≤ 0.0005) (Figure 3h). By the end of treatment, sDR5 had increased compared to diagnosis 
and approximated control levels (Figure 5.3h). During the first thirteen weeks (three months) 
of treatment, sDR5 was found to be very low in patients (irrespective of their month two 
status) and increased significantly at the end of treatment (p ≤ 0.0001) (Figure 5.3h). 
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Figure 5.3: Levels of soluble host markers in serum of controls and TB patients with fast 
and slow treatment response. Blood was collected pre-treatment and at week 1, 5, 13, and 26 
of treatment and ELISAs performed. (a) CRP, (b) sICAM-1, (c) suPAR, (d) sLAG-3, (e) 
granzyme B, (f) sTNFRI, (g) sTNFRII and (h) DR5 is shown. Control levels are represented 
by the horizontal dotted line.  
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5.3.4 Correlation between immune parameters and bacterial load as measured by the 
time to positivity 
The time to positivity (TTP) represents the time to detectable growth of M. 
tuberculosis in liquid culture (BACTEC of MGIT methods) and it is believed to be a measure 
of bacterial burden, where early growth detection in culture indicates a high bacterial load 
whereas delayed growth indicates low bacterial load. This part of the study assessed the 
correlation between immune parameters (CRP, sICAM-1, suPAR, sLAG-3, granzyme B, 
sTNFRs and DR5) and the time to positivity at diagnosis, week one and week five of 
treatment. The correlation between the different analytes and the TTP were established using 
the Spearman's rank correlation test, which is a test for correlation between sequences of pairs 
of values. No significant correlation was seen between the TTP and any of the immune 
parameters investigated. 
5.3.5 Early identification of fast and slow responders to anti-tuberculosis treatment 
Analysis including all immune parameters investigated 
Although individually the level of the markers investigated were not significantly 
different between the fast and the slow responders, the best set of variables with strong 
predictive power for month two sputum sterilization was subsequently determined using two 
different classification techniques, namely discriminant analysis (DA) and support vector 
machines analysis (SVM). A best subsets approach was used for each technique, where all 
combinations of variables were evaluated using leave-one-out cross validation. Due to the 
small sample size no single “best” model for each technique may apply, but all models that 
gave reasonable cross validation results were investigated and variables identified that 
appeared repeatedly in the models, these variables are presented in table 5.1. From this table 
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we see that sICAM-1 at diagnosis, CD3dim/CD56+ (% of CD45+) at diagnosis, 
CD3dim/CD56+ (% of CD45+) at week one and the difference in CD3dim/CD56+ (% of 
CD45+) between diagnosis and week one were the variables accentuated by both techniques. 
Cross validation classification results ranged from 75% to 100% correct classification for fast 
responders using DA and 82% to 100% for slow responders. For SVM, the correct 
classification results for the fast responders ranged from 88% to 100% and for the slow 
responders it ranged from 95% to 100%. The combinations of markers giving the best correct 
classification of both the fast and the slow responders are shown in table 5.2. 
Analysis including soluble parameters only 
The best set of variables with strong predictive power for month two sputum 
sterilization was determined as described above, only this time CD3dim CD56+ NKT-cells 
were excluded from the analysis. Results for cross validation classification using DA 
identified sICAM-1 (at diagnosis and week one), and CRP (at diagnosis and week one) as the 
best set of variables with predictive power for month two sputum culture conversion with 
62.5% correct classification for fast responders and 83.3% correct classification for slow 
responders. The SVM identified sTNFRI (week one) Granzyme B (diagnosis) and LAG-3 
(diagnosis) as the best set of variables with predictive power for month two sputum culture 
conversion with 87.5% correct classification for fast responders, and 72.7% correct 
classification for slow responders. 
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Table 5.1. Diagnosis and week one measurements entered in general discriminative and 
support vector machine analysis highest predictive models. Discriminant analysis and 
support vector machine analysis models gave 75% to 100% and 88% to 100% correct 
classification of patients into response groups respectively. 
Parameters 
General discriminative analysis 
# times entered out of 6 models 
Support vector machine 
Analysis # times entered out 
of 21 models 
sICAM-1 @ diagnosis 6 20 
CD3dim/CD56+ NKT cells 
(% of CD45+) @ 
diagnosis 
4 13 
CD3dim/CD56+ NKT cells 
(% of CD45+) @ week 1 
4 13 
CD3dim/CD56+ NKT cells 
(% of CD45+) between 
diagnosis and week1 
4 12 
CRP @ diagnosis 3 3 
CRP @ week1 3 1 
sICAM-1 week1 3 1 
Granzyme B diagnosis Not entered 4 
sTNFRII @ diagnosis Not entered 4 
sTNFRII @ week 1 Not entered 4 
sTNFRI @ diagnosis Not entered 3 
suPAR-diagnosis Not entered 3 
LAG-3 diagnosis Not entered 3 
Granzyme B week 1 Not entered 1 
sTNFRI week 1 Not entered 1 
LAG-3 week1 Not entered 1 
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Table 5.2. General Discriminant Analysis and Support Vector Machine Analysis best 
classification of fast and slow responders to therapy. Parameters were measured at diagnosis (Dx) 
and at week one (W1) after initiation of treatment and included C-reactive protein (CRP), soluble 
intercellular adhesion molecule-1 (sICAM-1), soluble urokinase plasminogen activator receptor 
(suPAR), soluble lymphocyte activation gene-3 (sLAG-3), granzyme B, tumour necrosis factor 
receptor one and two (sTNFR I & II), death receptors 5 (DR5), CD3dim/CD56+ NKT-cells and chest 
X-ray grading  
General Discriminant Analysis 
 
Fast responders Correct 
Classification after 
Cross Validation 
Slow responders Correct 
Classification after 
Cross Validation 
sICAM-1 Dx;| CRP-Dx | 
CD3dim/CD56+% -Dx | 
CD3dim/CD56+% W1 
87.50% 100% 
Support Vector Machine Analysis 
sICAM-1.Dx | CRP.Dx | CRP.W1 | 
CD3dim/CD56+% Dx 
100% 100% 
sICAM-1.Dx | CRP.Dx | Granzyme 
B.Dx | CD3dim/CD56+% Dx 
100% 100% 
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5.4 Discussion and conclusion 
Currently, ZN sputum smear and sputum culture conversion at month two after 
initiation of therapy are the only validated methods (157) for the evaluation of early treatment 
efficacy but both approaches have serious limitations. Sputum smear analysis lacks sensitivity 
and it takes several weeks before a sputum culture can be reported as negative (60 days was 
used in the present study). Other microbiological markers of treatment response, including 
Ag85 in sputum (158-160), need further validation. Host immune biomarkers may offer an 
alternative to microbiological readouts to assess early treatment efficacy. Here we show that 
combination of biomarkers measured before and one week after initiation of therapy hold 
promise as predictive markers for early treatment response.  
The function and the potential application of CRP,(161;162) sICAM,(81;154) 
suPAR,(79) LAG-3,(93) granzyme B(155) and sTNFRs(34;153;163) as single markers of 
disease activity and progression in M. tuberculosis infection and other diseases are well 
documented in the literature but these markers do not have a sufficient predictive ability on an 
individual level. Furthermore, few studies have included combinations of potential markers 
(151;152). The markers in this study were selected for their reported association with active 
TB and can be linked to different phases of host immune responses against TB. They include 
proteins associated with the acute phase inflammatory response (CRP), proteins associated 
with cell adhesion, stimulation and migration (sICAM-1; suPAR), proteins involved with 
regulatory T cell activation (sLAG-3) and apoptosis (granzyme B; sTNFRs; sDR5).  
The present study also shows that serological biomarkers such as CRP, sICAM-1 
granzyme B, sLAG-3 and suPAR correlate with radiological extent of pulmonary tuberculosis 
prior to treatment initiation, which is consistent with previous reports.(89;164;165) It is 
furthermore known that the extent of pulmonary disease as assessed by chest radiography 
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affects not only the time of sputum smear or culture conversion during anti-tuberculosis 
treatment but also relapse rates after cure at the end of 6-month therapy.(47;52;166;167) 
Therefore, baseline levels of CRP, sICAM-1 granzyme B, sLAG-3 and suPAR could be useful 
in ensuring a greater level of homogeneity of patient and aid in the stratification of patient 
groups entering clinical trials. 
Although the direct comparison of soluble immune parameters in fast and slow 
responders showed no statistically significant differences at any time point, changes over time 
after initiation of treatment pointed to significant differences between fast and slow 
responders to treatment.  
Compared to control levels, both patient groups had significantly higher pre-treatment 
levels of suPAR, sICAM-1 and CRP but only fast responders had increased sTNFRII levels 
suggesting an enhance pro-inflammatory response. Both responder groups had markedly 
suppressed levels of sDR5. By the end of the six month treatment period all marker levels had 
returned to control levels, except sTNFRII levels in fast responders. CRP levels normalised 
after one week of treatment but suPAR, sICAM-1 and DR5 levels only did so by week 26.  
Significant changes from pre-treatment levels occurred late during treatment for 
suPAR, sICAM-1 (slow responders only) and DR5 but already after one week for CRP. The 
rapid decrease of CRP, an acute phase protein involved in pathogen opsonization has 
previously been reported (161) and might be due to a drop in mycobacterial load soon after 
initiation of treatment. The prolonged increase in sICAM-1 and suPAR might indicate a 
continued mobilization of effectors cells to the site of infection to clear persistent 
mycobacteria. The delayed resolution of inflammatory markers has also been previously 
reported by Chan et al(168) regarding interleukin 2 receptor levels in active TB patients 
during treatment.  
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sLAG-3 levels in patients were not different from controls at diagnosis or week 26 but 
dropped sharply, although temporarily, to below the levels in non-diseased individuals at 
week five and 13 in fast responders and at week 13 in slow responders. LAG-3 protein acts as 
an immune system regulator via regulatory T cells and prevents excessive and detrimental 
responses.(92) In absence of LAG-3 regulatory T cells fail to control effector T cells.(92) The 
kinetics of LAG-3 production in this study suggests that immune regulation sets in after 
control of mycobacterial infection has been achieved and this may happen earlier in fast 
responders. 
TNFR-induced signalling promotes activation, differentiation, survival and death of 
different cell types, including lymphocytes.(169;170) TNFRI signalling directly promotes 
macrophage activation, granuloma formation,(171) cytotoxicity and apoptosis of infected 
cells(170), whereas TNFRII
 
signalling is important for thymocytes
 
and cytotoxic T cell 
proliferation (172), immune regulation(170) and counters suppressive activity of regulatory T 
cells (173). In excess, TNFRII may promote apoptosis by potentiating TNF/TNFR-1 
interactions (174;175). Therefore, levels of sTNFRs released during an infection reflect the 
state of immune activation. The interplay between activating and suppressive mechanisms 
may also reflect successful treatment. Fast responders demonstrated an earlier suppression of 
circulating LAG-3 than slow responders and concentrations of sTNFRII were higher than in 
controls throughout treatment. sTNFRI levels also increased significantly at week one of 
treatment only in fast responders. Together these markers suggest that fast responders have a 
more activated immune response during the early treatment period. The earlier LAG-3 
suppression may be in keeping with this concept as counter-regulatory mechanisms may 
become appropriate after successful control of pathogens by antibiotics.  
This study is one of the first to describe the profile of sDR5 in TB patients during 
treatment. DR5 interaction with tumor necrosis factor–related apoptosis-inducing ligand 
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(TRAIL) mediates apoptosis (176;177). No differences between responder phenotypes were 
found but the pronounced low levels of this marker during treatment until a sharp increase to 
control levels at week 26, suggested that some apoptotic mechanism may be down-regulated 
during active disease and return to normal once the pathogens have been cleared by 
chemotherapy. The suppressed DR5 dependant pathways observed here may be a host 
mechanism to limit apoptosis-associated toxicity (178). 
Although no single serological marker was found to clearly differentiate fast from 
slow responders when the two groups were directly compared, logarithmic models combining 
markers at diagnosis and one week after initiation of treatment gave decent predictions of 
sputum culture conversion after 8 weeks of treatment. The observations made in this study are 
of relevance since, the sputum culture status at the end of the intensive phase of treatment is 
linked to relapse rates(53;166). Furthermore it is encouraging that the markers with predictive 
ability also correlate with the extent of disease on x-rays, another validated risk factor for 
relapse (52;166;179). 
When CD3dim/CD56 + NK T-cells were not included for the classification analysis, 
the two different classification techniques used to classify responder phenotypes in this study 
identified different markers as important contributors to the models. This could suggest that 
the classification techniques are not accurate or that the number of cases used is inadequate. 
However, as all markers used in this study are non-specific and their levels reflect general 
levels of inflammation, the concept of predictive models using combinations of non-specific 
host markers of chronic inflammation may still remain valid. The challenge for the future will 
be to identify the strongest markers that contribute to such models.  It is also unclear how 
concurrent illness, including HIV infection, would affect the validity of such models. 
The host markers in this study may provide only an indirect indication of drug effect. 
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As successful chemotherapy decreases the bacterial load, the host immune response, which 
was previously activated but overwhelmed by uncontrolled active infection, is allowed to 
return to a normal state when suppressive immune mechanisms gradually turn off effectors 
responses. The different rates at which these secondary responses take place in fast and slow 
responders may provide important predictive information. In the present study all patients 
received the same standard therapy. An important step in the evaluation of promising 
predictive markers will include testing in clinical trials with different treatment regimens 
where marker expression will have to be correlated with differential microbacterial outcomes.  
The aim of TB drug biomarker discovery will include the identification of markers that 
can aid in the shortening of clinical trials of new anti-tuberculosis drug candidates and, 
thereby offset some of the challenges that face new TB drug development. Currently, the 
success of chemotherapy for TB relies on monitoring of recurrence in the first two years after 
completed treatment. This means that clinical trials for new anti-TB drug candidates have a 
long duration, which, against the background of a high failure rate of new drug candidates 
entering Phase II and III testing, provides a serious disincentive to pharmaceutical industry 
focus on this important area, particularly given the low profit margins due to predominance of 
TB in resource-poor settings. Although the present study did not investigate markers for 
relapse, surrogate or predictive biomarkers that provide an early indication of drug efficacy 
would significantly decrease the cost of clinical trials and accelerate development of new 
antibiotics for TB treatment. Additionally, biomarkers may allow stratification of treatment 
regimens with possibly shortening of treatment in a majority of patients that may not require a 
six month treatment period and intensified regimens in those with increased risk for poor 
response and relapse. 
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In conclusion, this study shows that the concept of biomarkers for the prediction of 
differential treatment responses using combinations of host markers holds promise and 
requires further prospective investigation to attain an optimal set of markers. 
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________________________________________________________ 
CHAPTER 6: Evaluation of Biomarkers in a Biological Context as Measures of 
Efficacy and Prognostic Tools in Early Response to Anti-tuberculosis Treatment 
Part 2: Differential Expression of Selected Immune Genes  
________________________________________________________________ 
6.1 Introduction 
Gene expression under specific conditions may be useful in establishing and 
understanding the nature of physiological alteration and linking this to a clinical phenotype. 
Mistry and et al (180) showed that the host gene expression patterns can discriminate between 
active, latent, recurrent, and cured tuberculosis. Importantly, the discrimination between 
recurrent and cured tuberculosis could be established at the time subjects were healthy. 
Furthermore, investigating adjunctive recombinant human interleukin-2 immunotherapy in 
multi drug-resistant TB subjects, findings by Johnson B et al (181) suggested that differential 
genes expression may provide an indication of antimicrobial response. 
The present study investigated, in fast and slow responders, the expression of genes for 
which the protein products have been shown to be part of antimycobacterial immunity and 
immunopathology. The targeted genes included: IL-4, IL-4δ2, TGF-, TGF-RII, Foxp3 and 
GATA-3. 
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6.2 Study design 
mRNA was extracted from nucleic acid-stabilised blood samples from twelve fast and 
eight slow responders to anti-tuberculosis treatment taken at diagnosis and at week one after 
initiation of treatment. The mRNA was reverse transcribed into cDNA and the expression of 
the targeted genes was analysed by mean of quantitative real-time PCR. The mRNA 
expression data from the target analytes was normalised using the expression of housekeeping 
genes as described in Materials and Methods 
6.3 Results and discussion
6. 3. 1. IL-4 and IL- mRNA expression in the fast and slow responders during 
treatment 
Background: The role of IL-4 in human tuberculosis is not fully understood yet. Although 
excess production of IL-4 during tuberculosis is associated with a depressed Th1 response 
(13;103) and increased disease severity (103;104), it has also been suggested that IL-4 might 
play a role in protective immunity against TB (105;182), as IL-4 up-regulates the expression 
of complement receptors and mannose receptors in general (182). Studies on IL-4 KO mice 
have generated contradictory data. Sugawara et al. (105) demonstrated that M. tuberculosis 
infected IL-4 knockout mice had higher M. tuberculosis colony-forming units compared to 
wild type mice, and therefore that IL-4 was required for the defence against mycobacterial 
infection. Conversely, a study done by Hernandez-Pando et al. (103) on IL-4 KO mice 
showed that the absence of IL-4 led to diminished bacterial growth. Furthermore, with the 
discovery of an IL-4 alternative spliced variant (IL-42) which has been shown to be an IL-4 
antagonist (183), it is believed that the balance between IL-4 and IL-42 may be important in 
the regulation of IL-4 effects (184). Therefore, the study of IL-4 should also include IL-42 to 
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allow a more complete understanding of IL-4 biology as studies have shown that IL-42 
competes very effectively with IL-4 for their common binding sites. 
IL-4 mRNA expression in fast and slow responders using primers that amplified both IL-4 and 
IL- mRNA reversed transcripts.
The comparison of IL-4 mRNA expression (no discrimination between the different 
types of IL-4) at diagnosis (p-value = 0.23) and at week one (p-value = 0.06) showed no 
statistically significant differences between fast and slow responders (table 6.1). However, the 
analysis of IL-4 mRNA expression change over time within each group showed that the 
changes in IL4 mRNA transcripts in the fast responders between diagnosis and week one were 
significant (p-value = 0.018) and up regulated by a factor of 7.68. No significant changes were 
observed in IL4 mRNA transcription in the slow responders between diagnosis and week one 
after the treatment was initiated (table 6. 2). 
Quantification of IL-4 mRNA expression in fast and slow responders using IL-4 specific 
primers and IL- specific primers.  
The use of primers specific for IL-4 and IL- showed no statistically significant 
differences in IL-4 and IL- between fast and slow responders at diagnosis. At week one 
only IL-4 mRNA transcription showed significantly different transcription between groups 
with the fast responders showing significantly higher level of IL-4 mRNA transcripts than the 
slow responders (p-value = 0.038; table 6.1). IL- was transcription was 2.13 times higher 
in the fast responders compared to the slow responders but the statistical analysis showed no 
significance (p-value = 0.083). 
The changes from diagnosis to week one of treatment for IL-4 and IL- mRNA 
transcription in the individual groups showed that slow responders significantly down 
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regulated IL-4 by a factor of 0.06 (p-value = 0.002) whereas IL- mRNA transcription was 
significantly up regulated by a factor of 47.32 (p-value = 0.0001) (table 6.2). The 
simultaneous down regulation of IL-4 mRNA transcripts and up regulation of IL- mRNA 
transcripts in the slow responders may have resulted in the absence of significant changes in 
IL-4 mRNA transcription at week one in experiments with primers that amplified both the 
reverse transcripts of IL-4 and IL-. In the fast responders no significant changes in IL-4 
transcription was observed between diagnosis and week one (p-value = 0.69). However IL-
 transcription was significantly up regulated by a factor of 18.93 (p-value = 0.026) after 
one week of treatment (table 6.2). Thus the significant changes in IL-4 mRNA transcripts 
observed in fast responders between diagnosis and week one when non-specific primers were 
used was most probably due to the contribution of IL-2 mRNA transcripts. 
The biological explanation of the up regulation of IL-2 resulting in a decrease of the 
IL4/IL-42 ratio (Figure 6.1) from 176 to 2.96 in the fast responders and from 212 to 1.1 in 
the slow responders after one week of treatment (Figure 6.1a-b) may lie in a drop in bacterial 
load which could allow the immune system to adopt immune regulatory mechanisms. It is not 
clear whether the differences in IL-4 transcript regulation described above are a consequence 
of or mechanistically involved in the rate of sputum culture conversion. A certain level of IL-4 
may be required to sustain complement receptors and mannose receptor expression and 
promote phagocyte killing of bacteria in parallel to drug associated killing. The requirement of 
IL-4 for the defense against mycobacterial infection has been shown in the past (105). Another 
possible explanation could be that higher levels of IL- 4 in the fast responders were the 
consequence of increased apoptosis that occurred in this group as suggested by the findings of 
Veenstra H et al (185). Veenstra H et al postulated that “IL-4 was secreted by cells as 
autocrine/paracrine growth factor and that the secretion ceases at the onset of apoptosis, 
leading to accumulation of IL-4. Interestingly from a potential biomarkers prospect, the 
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changes in of IL-4 and IL- regulation during early treatment and the differences between 
the responder groups may position these analytes as potential valuable predictor of treatment 
response that need to be investigated further in large scale studies. 
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Figure 6.1: (a-b) IL4/IL-42 expression ratio at diagnosis and at week one after 
initiation of treatment. IL4/IL-42 ratio declined from 176 to 2.96 in the fast 
responders and from 212 to 1.1 in the slow responders after one week of treatment 
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6. 3. 2. TGF- and TGF-RII mRNA expression between fast and slow responders 
during treatment.  
TGF- has been documented to impair host protective immunity to Mtb (110-112). 
TGF-RII expression is required for cellular responses to TGF- and may also inhibit host 
immunity. In addition, it has been shown that the Lipopolysaccharide (LPS) inflammatory-
induced response or IFN- decreases TGF-RII expression, which is accompanied by a 
diminished ability
 
of the cells to respond to TGF-Patients with active TB have 
increased expression of TGF- mRNA (187). Furthermore, the level of TGF- and TGF-RII 
expression in active TB patients were shown to be significantly higher compared to cured 
patient (112). Interestingly, Hirsch CS et al showed the degree of suppression decreased with 
the time on treatment (114) 
In the present study, no differences in the expression levels of TGF-or TGF-RII 
were found between the fast and slow responders to treatment at diagnosis (p-value [TGF-] = 
0.793; p-value [TGF-RII] = 0.545) or at week one (p-value [TGF-] = 0.22; p-value [TGF-
RII] = 0.2) (table 6.1). No significant changes in TGF-or TGF-RII expression were 
observed between diagnosis and week one in either the fast or the slow responders (table 6.2). 
The data suggest that TGF- and TGF-RII expression pre-treatment and early after the 
start of treatment did not capture the events that influenced week eight sputum culture 
conversion. 
6. 3. 3. FOXP3 mRNA expression in fast and slow responders during treatment.  
Foxp3 is a transcription factor expressed by CD4+ CD25+ regulatory T-cells and these 
cells have been shown to be involved in immune suppression (40;42). Robert T et al (119) 
have recently shown that mycobacterium associated immunosuppression in active TB patients 
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was most likely mediated by naturally occurring regulatory T cells. To investigate the 
association of regulatory T-cells with month two sputum culture conversion, we measured the 
expression levels of FOXP3 in the fast and slow responders at diagnosis and at week one after 
initiation of therapy. 
No difference in the expression level of FOXP3 was found between the fast and slow 
responders to treatment at diagnosis (p-value = 0.88) or at week one (p-value = 0.17) (table 
6.1). Fast responders showed an increase in FOXP3 by a factor of 5.03 (p-value = 0.11) after 
one week of treatment, whereas the slow responders showed only a 1.95 factor increase (p-
value = 0.34) (table 6.2). However, the changes in FOXP3 expression recorded in the fast or 
slow responders were not statistically significant most probably due the large standard error in 
FOXP3 expression recorded in the groups. Nevertheless, FOXP3 as a potential predictor of 
week eight sputum culture conversion cannot be ruled out completely. Further studies 
including more patients and additional time points should be considered. 
6. 3. 4. GATA-3 mRNA expression in fast and slow responders to treatment  
GATA-3 is a Th2 cell-specific transcription factor that has been reported to control 
Th2-specific cytokine expression and to function as a negative regulator of the development of 
Th1 cells independently of its ability to up regulate Th2-type cytokines (115;116;188). The 
presence of Th2 type responses in patients with active TB has been shown to be associated 
with the radiological extent of pulmonary disease (189). As the extent of disease is a risk 
factor for delayed sputum conversion in TB patients under treatment, GATA-3 expression at 
diagnosis or at week one after the initiation of anti-tuberculosis therapy was investigated.  
No significant differences between fast and slow responders at diagnosis (p-value = 
0.52) or week one (p-value = 0.065) (table 6.1) were found. Although the differences between 
fast and slow responders were not statistically significant, GATA-3 mRNA expression was 
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3.84 fold higher in the fast responders than in the slow responders at week one (p-value = 
0.06). Fast responders showed an increase in GATA-3 by a factor of 3.61 (p-value = 0.13) 
after one week of treatment, whereas slow responders had a 1.5 factor increase (p-value = 
0.42) (table 6.2). These changes were not statistically significant but large standard errors in 
FOXP3 expression could affect the significance.  
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Table 6. 1: Differential mRNA expression between the fast and the slow responders 
during treatment (diagnosis and week one after initiation of treatment). The expression 
factor in the table represent the the level of expression of the transcripts in the fast responders 
when compared to the slow responders. 
 Diagnosis 
n = 20 
Week one 
n = 20 
Analytes 
Mean 
Expression 
factor 
Standard 
error 
p-
value 
Mean 
Expression 
factor 
Standard 
error 
p-
value 
IL-4* 
0.396 (lower 
regulation in 
fast 
responders) 
0.038 - 
3.37 
0.23 
2.12 (higher 
regulation in 
fast 
responders) 
0.82 - 4.83 0.06 
IL-4 
6.7 (higher 
regulation in 
fast 
responders)  
0.05 - 4400 0.24 
1.75 
((higher 
regulation in 
fast 
responders) 
0.9 – 2.94 
0.038 
 
IL-42 
0.68 (lower 
regulation in 
fast 
responders) 
0.029 – 8.9 0.45 
2.13 (higher 
regulation in 
fast 
responders) 
0.58 – 8.3 0.083 
TGF- 1.01 0.12 - 6.83 
0.793 2.58 (higher 
regulation in 
fast 
responders) 
0.139 – 26. 0.22 
TGF-RII 
1.350 
(higher 
regulation in 
fast) 
0.13 - 
13.48 
0.545 3.4 (higher 
regulation in 
fast 
responders) 
0.21 -71.42 0.2 
FOXP3 
0.892 (lower 
regulation in 
fast 
responders)  
0.088 - 
8.17 
0.880 2.7 (higher 
regulation in 
fast 
responders) 
0.5 - 15.17 0.17 
GATA-3 
1.387 
(higher 
regulation in 
fast) 
0.178 - 
12.3 
0.520 3.84 (higher 
regulation in 
fast 
responders) 
0.75 -28.92 0.06 
 
(*) = Primers used amplified both IL-4 and IL42                                            = Significant p-value 
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Table.6.2. mRNA expression changes between diagnosis and week one after initiation of 
treatment 
 Fast Responders 
n = 8 
Slow Responders 
n = 12 
Analytes 
Mean 
Expressio
n factor 
Standard 
error 
p-value 
Mean 
Expression 
factor 
Standard 
error 
p-
value 
IL-4* 
7.68 (up 
regulated 
at week 
one) 
1.5 - 36.96 0.018 
2 (up 
regulated) 
0.37 -11.16 0.3 
IL-4 
0.71 (down 
regulated) 
0.11 – 7.13 0.69 
0.06 (down-
regulated) 
0.26 – 0.98 
0.002 
 
IL-42 
18.93 (up 
regulated) 
0.6 – 488.3 0.026 
47.32. (up 
regulated) 
4.01–703.4 
0.0001 
 
TGF- 
2 (up 
regulated) 
0.091 - 22.5 0.4 0.94 0.12 - 6.61 0.74 
TGF-RII 
2.25 (up 
regulated) 
0.17 - 43.41 0.39 1.1 0.087 -14.4 0.71 
FOXP3 
5.03 (up 
regulated) 
0.51 - 43.98 
0.11 
1.95 (up 
regulated) 
0.25 - 21.1 0.34 
GATA-3 
3.61.(up 
regulated) 
0.34 - 29.18 
0.13 
1.5 (up 
regulated) 
0.18 - 13.4 0.42 
 
(*) = Primers used amplified both IL-4 and IL42                                            = Significant p-value 
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6.3.5 Genes expression and extent of tuberculosis as defined by chest x-ray radiography 
Previous studies have reported Th2 type response mainly IL-4 (190) to be associated 
with the extent of disease. However, in the present study no associations between Th2 type 
response as measured by IL-4 and GATA-3 mRNA transcription and chest x-ray presentations 
of the disease were found (table 6.3). Other immune parameter that play a role in TB 
immunopathology namely IL-4δ2, TGF-, TGF-RII, and Foxp3 were also investigated for 
their association with chest x-ray presentations of the disease. The data showed no association 
between chest x-ray radiography grading of pulmonary extent of disease and the immune 
parameter investigated 
6. 1. Conclusion  
This study showed that fast and slow responders had differential gene expression 
following initiation of treatment. This observation suggests that treatment induced changes in 
mycobacterial infection are associated with measurable physiological changes in the host that 
may carry information on treatment outcome as postulated in the starting hypothesis of this 
study. Further investigations are needed to elucidate the underlying causes of the differences 
observed between fast and slow responders during anti-tuberculosis treatment. 
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________________________________________________________ 
CHAPTER 7: General Discussion, Future Work and Implementations 
_________________________________________________________________ 
7.1 General discussion 
 Despite the implementation of DOTS and its relatively good coverage (global 
coverage: 89%), the incidence of tuberculosis worldwide remains a cause for concern (6). 
Therefore it is necessary to develop new strategies for the development of anti-tuberculosis 
drugs and the treatment of tuberculosis. The current standard treatment strategy do not allow 
for stratification of patients into different treatment arms and the majority of patients may be 
receiving excessively long treatment regimens whereas a minority with an increased risk for 
poor outcome are receiving inadequate treatment regimens. The exceptions are patients with 
previous tuberculosis who receive additional drugs and follow a longer treatment duration that 
cases with a first episode. Currently no particular emphasis is placed on the extent of disease 
at diagnosis, although failure to sterilise the sputum culture and multi-drug resistance have 
been shown to be associated significantly with cavitary tuberculosis (46).  
 Furthermore, the only evaluation of treatment response comes after the intensive phase 
of therapy, which is two months after the initiation of treatment. The relatively long time 
between treatment initiation and the first evaluation of its effectiveness raises some concerns, 
as two-month suboptimal treatment may increase the risk for the development of drug 
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tolerance or resistance in some patients (46;148;149). Thus biomarkers of extent of 
tuberculosis disease and treatment effectiveness that can easily be measurable in resource 
constrained settings early after the onset of therapy may therefore have a significant clinical 
impact by decreasing the risk of the development of drug tolerance and resistance, as these 
biomarker will allow the identification of patients at increased risk for poor treatment 
outcome. 
New multiplex assays based on the Luminex X-map technology, which in theory 
enable the simultaneous measurement of up to 200 plasma proteins, may become important 
tools in the ongoing search for biomarkers. This thesis evaluated commercially available kits 
using this technology and shows that these assays are able to perform with reasonable 
accuracy and that this technology may hold promise in the targeted search for biomarkers. 
However, proper optimisation needs to be performed and adequate controls need to be 
included. 
 This thesis also demonstrated that the extent of pulmonary tuberculosis disease affects 
the profile of the patient immune parameters (granzyme B, CRP, sICAM-1, sLAG-3, suPAR 
and sTNFRI) at diagnosis. It was also demonstrated that the direct comparison of the fast and 
slow responders on the basis of the selected immune parameters showed no statistically 
significant differences. However, comparison of different responder groups with healthy 
community controls unmasked certain differences between them, as demonstrated by the level 
of suPAR, sICAM-1, sLAG-3, sTNFRII and sTNFRI for selected time points. This may 
indicate that larger numbers of cases are needed to increase the power of the studies. One 
other important observation in the study was that even small changes that are not perceived as 
significant by conventional statistical analysis were able to segregate fast from slow 
responders with high accuracy when combined in multivariant logarithmic models. Moreover, 
mRNA transcription analysis of selected genes showed that the fast and slow responders had 
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differential gene expression following the initiation of treatment. It was evident that the fast 
responders had overall enhanced levels of immune regulatory markers after introduction of 
treatment compared to slow responders. The findings made in this study support the concept 
that non-specific biomarkers for TB treatment response hold promise and that the underlying 
differential response to antimycobacterial therapy results in differences in immune reactions 
that can be used to identify patient with a high risk for a poor treatment outcome. This is of 
great significance as this proof of concept will most certainly motivate researches on TB 
biomarkers discovery and ultimately lead to the development and validation of new 
therapeutic strategies that will allow the right treatment for the right patients at the right time. 
7.2 Future work and implementations 
7.2.1 Goals and Objectives 
The goal of future studies would be to discover stronger host biomarkers for human 
tuberculosis disease status and treatment outcome. The hypothesis underlying such a project is 
that the molecular composition of the host’s body fluids, which can be characterised by 
modern bioanalytical techniques, reflects disease status and response to drug therapy. A 
broad-spectrum molecular analysis of body fluid samples from well-characterised TB patients 
and advanced analytical capabilities is being planned. The objectives will be to identify 
predictive biomarkers of cure versus relapse, to verify and validate biomarkers highlighted in 
this thesis and to select biomarkers for assay development.  
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7.2.2 Project Design 
Sample collection at Stellenbosch University (SU) 
Three hundred and thirteen adult HIV-negative new TB patients were enrolled prior to 
directly-observed short course (six month) treatment. Samples were collected longitudinally 
during treatment and for two years following therapy, and carefully catalogued and stored. 
This sample collection is believed to be a unique resource and includes plasma, serum, urine, 
live Mycobacterium tuberculosis (Mtb)-stimulated whole blood culture supernatant and 
corresponding RNA and ex vivo RNA. The patients can be stratified into treatment responder 
phenotypes: fast (48%) or slow responders (52%) at month two of therapy; cured (n = 211) or 
failed treatment (n = 5) after six months of therapy; or recurrence (n = 22) within 30 months 
of diagnosis. For the proposed study, samples from 19 patients with recurrence and 153 
without recurrence are available (Figure 8.1). The time point of sputum smear or culture 
conversion and time-to-positivity (TTP) in BACTEC culture at different times during therapy 
are known for each patient. Patients with drug-resistant TB, poor treatment adherence and 
HIV infection were excluded from the full study. This sample collection will be mined for 
molecular signals that predict outcome and thereby generate sufficient preliminary data to 
facilitate future biomarker research and justify more extensive prospective studies. 
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Figure 8.1: Overview of sputum smear and culture conversion and outcomes at 30 months in  new 
smear-positive pulmonary tuberculosis patients (n=263 All smear and culture results are reported as 
the number of patients who attended follow-up visits, who could produce sputum and for whom results 
were available. Missing data were as follows: week 2 smear (14), week 2 culture (21), month 1 smear 
(18), month 1 culture (34), month 2 smear (21), month 2 culture (32), month 3 smear (31), month 3 
culture (80), month 6 smear (44), and month 6 culture (67). 
Month 6  
Smear+: 6 (2.3%)  
Culture +: 11 (4.2%) 
 
 
 
Month 2  
Smear+: 66 (25.1%) 
Culture+: 136 (51.7%) 
Screened: N = 313 
 
Enrolled: N = 263 (TTP not available: n=26)             
Exclusion criteria (n= 50) 
 
 HIV-infected (n=14) 
 Other co morbidity (n= 4) 
 Multidrug resistance (n=8) 
 Non-tuberculous mycobacterial (n=2) 
 Other lung disease (n= 6) 
 Early protocol violators (n=3) 
 Previous tuberculosis (n=2) documented 
subsequent to enrolment  
 Not smear positive at retesting in the research 
laboratory (n=11) 
Month 1  
Smear+: 139 (52.9%) 
Culture+: 199 (75.7%) 
Month 3  
Smear+: 18 (6.8%)  
Culture +: 38 (14.4%) 
 
 
%) 
Week 2  
Smear+: 200 (76.0%) 
Culture+ 224 (85.2%) 
International month 6 treatment outcomes (n=263) 
 
Favourable: N =211 (80.2%) 
 Treatment completed: 20/263 (7.6%) 
 Cured: N =191/263 (72.6%) 
 
Unfavourable: N =52 (19.8 %) 
 Treatment failure: N=5/263 (1.9 %) 
 Defaulted: N=45/263 (17.1 %) 
 Transferred out: N=2/263 (0.8%) 
 Death: N=0 (0%) 
Causes of death  
 Myocardial infarction (1) 
 Trauma (2) 
 Pneumonia (1) 
 Documented as natural cause (1) 
Retreatment after completion of therapy with favorable 
outcomes: N = 22/211 (10.4 %) 
 Retreatment after cure: 18/191 (9.4%) 
 Retreatment after treatment completion: 4/20 (20%)  
 
 Re-infection: 6 (27.3%); 6/211 (2.8% re-infection) 
 Relapse: 12 (54.5%); 12/211 (5.7% relapse) 
 Unclassified: genotyping not available: 4 (18.2%); (1.89%) 
30-month outcomes (N=211) 
 Death: N=5 (2.4%) 
 Retreatment: N = 22 (10.4%) 
 Seen and well: N = 153 (72.6%) 
 Documented moved: N =10 (4.7%) 
 Lost to follow-up: N = 21 (9.6%) 
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Patients selection 
Sixty representative patients will be selected (with a full complement of sample sets) 
in a case cohort study design with the following groups: 1) 12 patients with relapse of TB 
within two years of bacteriological cure after standard six-month anti-TB therapy, and 2) 40 
randomly-selected patients who were cured after six months of therapy and did not develop 
relapse with TB within two years of treatment completion. All the patients will be well-
characterised, with documented drug-sensitive Mtb strain infection and good treatment 
adherence. Both patient groups will include patients with different smear, culture and TTP 
status at different time points. This approach will allow the correlation of marker expression 
with active, and subsequently inactive, disease.  
Plasma, serum, ex vivo RNA, urine, Mtb-stimulated whole blood culture supernatant 
and corresponding RNA will be used. Time points for analysis will include pre-treatment, 
week one, week two, week four, week twenty-six (end) of treatment and week fifty two (six 
months after treatment completion).  
Analytical platforms 
a) Targeted marker analysis 
Promising biomarker such as suPAR, sICAM-1, CRP, sLAG-3 and IL-4 that were 
identified by the present study plus TNF-IFN-, IL- IL-1, IL-1r, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, G-CSF, GM-CSF, 
MCP-1, MIP-1, MIP-1, TGF-, sCD40L, EGF, VEGF, Eotaxine and Fractalkine will be 
measured by ELISA and multiplex cytokine arrays in serum and Mtb-stimulated whole blood 
culture supernatant.  
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b) Metabolomic and proteomic analysis of plasma and urine samples 
In collaboration with experts in the field specialised mass spectrometry, 
chromatography and nuclear magnetic resonance spectroscopy platforms will be used to 
measure and identify biological molecules present in the plasma and urine samples. 
c) Transcriptomic analysis of ex vivo RNA and of RNA from live Mtb-stimulated whole blood 
culture 
In collaboration with experts in the field gene expression profiles will be characterised 
by hybridisation to Affymetrix Human Genome U133 Plus 2 microarrays. RNA from ex vivo 
blood samples will be tested to assess gene mRNA expression changes between diagnosis and 
week one after initiation of treatment expression, allowing comparison with results from 
analyses of serum or plasma proteins.  
d) Statistical analysis and interpretation of transcript, protein and metabolite datasets 
In collaboration with experts in the field data processing and statistical analysis 
approaches will be customised for the types of molecular data generated by the measurement 
technologies. Initially, univariate analysis to identify molecular measurements that are 
statistically related to the clinical measures of interest will be used. Specialised and distinct 
analysis modules to identify biomarkers for diagnosis, prognosis, treatment response 
prediction and patient monitoring, including predictive statistical modelling, exploratory 
clustering and correlation networks, will be used to evaluate the association of each measured 
molecule, alone (univariate) or in combination with other molecules (multivariate), with the 
desired outcome. 
Expected outcomes and implementations  
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The project will make use of a unique sample collection obtained during treatment 
from well-characterised TB patients who were then followed up for two years following cure. 
Although the number of relapsed patients is relatively small (n = 12), based on power 
calculations performed on simulated datasets, the prospects for discovering predictive markers 
for cure versus recurrence are good. In addition, the project will have sufficient power to test 
whether surrogate markers for bacteriological cure can be identified by a combination of 
‘omics’ approaches and accompanying advanced statistical modelling. 
In addition, the project will lead to important insights into the design issues for future 
prospective studies of biomarkers in this field, including the types of biological samples that 
prove to be useful for this purpose. Another benefit will be biomarkers that can aid in 
shortening clinical trials of new anti-tuberculosis drug candidates, and thereby facilitate the 
ultimate approval of new drug therapies. Because evaluating the success of chemotherapy for 
TB currently relies on monitoring of recurrence in the first two years after treatment is 
complete, clinical trials for new anti-TB drug candidates have a long duration which, against 
the background of a high failure rate of new drug candidates entering Phase II and III testing, 
provides a serious disincentive to pharmaceutical industry focus in this important area. A 
further disincentive for new anti-TB drug development is the high incidence of TB in 
resource-poor settings, which means that pharmaceutical companies selling anti-TB drugs 
operate in markets with low profit margins. Surrogate biomarkers that provide an early 
indication of drug efficacy, or predictive biomarkers for cure versus recurrence, would 
significantly decrease the cost of clinical trials, accelerate development of new anti-TB 
therapies and, ultimately, increase their availability.  
New drugs and shorter treatment regimens are urgently needed, as about nine million 
people worldwide develop active tuberculosis annually and the provision of directly-observed, 
six-month therapy places an unacceptably high burden on TB control programmes in 
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developing countries, where the disease is most prevalent. Also, new drugs are essential to 
address the growing number of multi-drug resistant (MDR) and extensively drug resistant 
(XDR) strains that are emerging worldwide 
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